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ABSTRACT 
Jordan Emile Cates: Malaria and Malnutrition during Pregnancy: An Investigation of 
Interactions and Interventions.  
(Under the direction of Daniel J. Westreich) 
 
Malnutrition and malaria infection commonly co-exist, afflicting pregnant women in 
resource-poor settings and increasing the risk of a low birthweight (LBW) infant. By 2025, 
WHO targets a reduction in the incidence LBW by 30%. Previously, four studies indicated that 
the effect of malaria infection on the risk of LBW may depend upon maternal nutritional status.  
We evaluated the interaction between maternal malaria infection and maternal 
anthropometric status on the risk of LBW using data from 14,633 pregnancies from 13 studies 
conducted in Africa and the Western Pacific. Study-specific adjusted effect estimates were 
calculated using inverse probability of treatment-weighted linear and log-binomial regression 
models and pooled using a random effects model. Using parametric g-formula, we estimated 
population-attributable effects and generalized intervention effects for differences in the 
incidence of LBW expected under hypothetical malaria and malnutrition interventions.  
The adjusted risk ratio (aRR) for delivering a baby with LBW was 1.14 (95% CI: 0.91, 
1.42) among women with malaria infection at antenatal enrollment, 1.32 (95% CI: 1.08, 1.62) 
among women with malaria infection at delivery, and 1.60 (95% CI: 1.36, 1.87) among women 
with low mid-upper arm circumference at enrolment (MUAC <23cm). The joint aRR for women 
with both malaria infection and low MUAC at enrollment was 2.13 (95% CI: 1.21, 3.73; 
 iv
N=8,152). There was no evidence of synergism between malaria infection and MUAC on the 
multiplicative (p=0.5) or additive scale (p=0.9). We estimated that, compared to the current 
patterns of IPTp use in the study population, increasing every woman’s dosage of IPTp to at least 
three doses would result in a relative decrease in the incidence of LBW of 34% (95% CI: 25%, 
43%). The intervention effects for malaria at delivery, low MUAC in early pregnancy, and bed 
nets were all modest. 
Pregnant women with malnutrition and malaria infection are at increased risk of LBW, 
but malaria and malnutrition do not act synergistically. Scale up of IPTp, alone or in tandem with 
other antenatal interventions, could help achieve the WHO’s Global Nutrition Target of a 30% 
reduction in LBW by 2025. 
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CHAPTER I: SPECIFIC AIMS 
 
In malaria endemic countries, up to one in four pregnant women are infected with 
malaria during pregnancy (1). A major consequence of maternal malaria infection is low 
birth weight (1–3). Malaria doubles the risk of low birth weight (LBW) and may contribute to 
up to 25% of LBW infants in endemic countries (2,4). LBW can have a profound impact on 
neonatal mortality and childhood morbidity, affecting multiple aspects of mental, metabolic, and 
anthropometric development (5). These risks persist despite scaling up of malaria prevention 
programs targeted towards pregnant women, such as intermittent preventive therapy during 
pregnancy (IPTp) and bed-net campaigns (1,2,5,6). Consequently, there is an urgent need to 
understand the effects of malaria on the developing fetus and how malaria prevention during 
pregnancy can improve pregnancy outcomes (7). 
 In resource-poor settings, malaria infection and malnutrition commonly co-occur in 
pregnant women. Recent evidence indicates that the harmful impact of malaria on fetal 
growth and LBW may depend upon the nutritional status of the mother (8–10). In a few 
small studies conducted in malaria endemic areas, malaria increased the risk of LBW only 
among malnourished women, and not among well-nourished women (8,9), however two 
additional studies found contradictory results (11,12). One study found that the risk of 
intrauterine growth restriction associated with malaria was consistently two to eight times higher 
among women with evidence of macronutrient malnutrition (8). Not only are these studies 
somewhat inconsistent in their findings, but our confidence in their interpretation is hindered by 
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their small sample size and potential lack of generalizability. Understanding the potential 
synergistic relationship between malaria and malnutrition could identify possible pregnancy 
interventions that improve fetal growth and prevent infant morbidity and mortality.  
Furthermore, it is unclear how hypothetical, realistic interventions to improve both 
maternal nutrition and prevent malaria could impact population-level pregnancy outcomes. 
State-of-the-art epidemiologic methods exist that allow us to model the impact of plausible 
targeted antimalarial and malnutrition interventions during pregnancy could have on the number 
of LBW infants in malaria endemic areas (13–15).  
We conducted a pooled analysis utilizing data from 14,633 singleton, live birth 
pregnancies across thirteen completed studies conducted in malaria-endemic areas (Africa and 
Western Pacific) (Aim 1). We also used this pooled data to implement statistical modeling to 
explore the impact of hypothetical targeted antimalarial and nutritional interventions on 
population-level pregnancy outcomes (Aim 2). 
Specific Aim 1: To investigate the joint effects of malaria infection and maternal 
malnutrition during pregnancy on the risk of LBW. We hypothesized that there would 
be a synergistic interaction between malaria infection and malnutrition in causing LBW, 
such that the observed joint effect of being both infected with malaria and malnourished 
would be greater than expected if considering each exposure independently. 
Specific Aim 2: To explore the impact of realistic interventions to improve maternal 
nutritional status and targeted antimalarial interventions on population-level 
pregnancy outcomes. We simulated multiple plausible interventional contrasts using the 
parametric g-formula to assess the impact of targeted antimalarial and nutrition 
interventions.  
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This work has significant impact on public health by providing evidence on the malaria-
malnutrition-LBW relationship and the effect of hypothetical interventions on this relationship. 
Our study is innovative in its utilization of robust extant data and exploration of the effect of 
realistic interventions. These results identified effective interventions to help address the burden 
of adverse pregnancy outcomes and improve clinical practice among this population. 
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CHAPTER II: BACKGROUND AND SIGNIFICANCE 
Low Birthweight 
Annually, over 20 million infants are born with low birthweight (LBW), defined as birth 
weight less than 2,500 grams (16). This constitutes 15% to 20% of all births worldwide. LBW is 
of global health concern, but low- and middle-income countries (LMICs) are disproportionately 
affected, with estimates as high as 28% in south Asia and 13% in sub-Saharan Africa (16). One 
recent study that accounted for potential underestimation of LBW due to deliveries in homes or 
smaller health clinics estimated that approximately 32.4 million babies were born small-for-
gestational age (SGA) in 2010, representing 27% of all births in LMICs (17). 
Low birthweight (LBW) is associated with a nine-fold increase in neonatal mortality 
(death within the first month) and a three-fold increase in infant mortality (death within the first 
year) (18,19). Thus, even though the prevalence of LBW is only 15-20% worldwide, it is 
estimated that LBW babies account for 60-80% of neonatal deaths (20). In addition to the 
contribution to infant mortality, LBW leads to long-term morbidities, specifically affecting 
mental, metabolic, and anthropometric development (16). Behavioral development, demonstrated 
by school performance and academic achievement, has been negatively associated with LBW 
(19). Because of these negative health associations, the World Health Organization (WHO) has 
included a 30% reduction in LBW as one of the 2025 Global Nutrition Targets (16). As of 2014, 
the Global Nutrition Report found that there was little progress towards this target (21). 
Interventions in LMICs to improve fetal growth have the potential to produce substantial public 
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health effects, improving a wide array of factors ranging from cognitive development to 
enhanced neonatal survival, assuming causality between LBW and these factors.  
Birth weight is easily measured with maximal precision, making it a feasible marker of 
high-risk infants in low-resource settings. However, birth weight is not without its own 
limitations. Many LMICs use Salter Scales with variable precision, and infants born at home are 
often not weighed at all. Historically LBW has been dichotomized at less than 2500 grams based 
on evidence of marked mortality among this high-risk group of infants (3). LBW does not correct 
for gestational age at birth, and can result from premature delivery of the infant, intrauterine 
growth restriction (IUGR), or both (3,22,23). Although IUGR and preterm birth share common 
risk factors, they are two distinct phenomena with differing etiology, and LBW does not 
differentiate between the two (3). One recent study estimated that approximately half of LBW 
babies in low- to middle-income countries are preterm (23), higher than previously assumed (24). 
When reliable estimates of gestational age are available, SGA is often used as a proxy for IUGR. 
SGA is defined as a birth weight below the 10th compared to other infants at the same gestational 
age using a published and validated referent (3,25,26). However, diagnosis of SGA, as well as 
preterm birth, requires reliable gestational age assessment, preferably using ultrasound 
pregnancy dating, which limits its feasibility as a measure in most resource-limited settings.  
 
Malaria during pregnancy 
Extent and impact of malaria infection during pregnancy 
Malaria infection during pregnancy affects more than 25 million pregnant women 
annually, producing detrimental effects on maternal, newborn, and infant health (1–3). Over 125 
million pregnant women are at risk for malaria in areas of stable and unstable P. falciparum 
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and/or P. vivax malaria transmission in most parts of Africa and select areas of Central and 
South America, Asia, and Western Pacific regions (4).  
A major consequence of maternal malaria infection is LBW (1–3). The most predominant 
malaria parasite species, Plasmodium falciparum, has the unique capability of sequestering in the 
placenta, causing adverse sequelae (27). In low transmission settings, pregnant women typically 
present with severe, symptomatic disease when infected with malaria, resulting in maternal and 
infant mortality. However, in malaria-endemic high-transmission areas, maternal mortality due 
to malaria is less frequent (although still exists) due to increased maternal immunity, but 
infection remains frequent and deleterious for fetal growth and preterm delivery (27,28). In 
malaria-endemic settings, 20-50% of LBW has been attributed to malaria infection during 
pregnancy (1,2,19). Malaria doubles the risk of LBW, and that effect is even greater among 
women who are pregnant for the first time (primigravid) or second time (secundigravid) (1). 
Immunological studies have identified that sera from the placenta of multigravid women, but not 
primi- or secundigravid women, are able to bind/aggregate parasites (19). This physiological 
phenomenon of parity-specific immunity supports the epidemiologic studies identifying greater 
susceptibility and harmful impact of malaria among primi- and secundigravid women. In 
addition to gravidity, HIV infection also modifies the effect of malaria on LBW, with a larger 
impact of malaria on LBW found among HIV-infected women (1,29). HIV further increases the 
risk of placental malaria, febrile illness, and higher parasitic densities (1,29). However, there are 
conflicting results as to whether or not placental malaria increases the risk of mother to child 
transmission of HIV (1).  
There are five species of malaria-causing Plasmodium parasites (falciparum, vivax, ovale, 
malariae, and knowlesi) that can infect pregnant women. P. falciparum is the most virulent 
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because it cytoadheres (sticks) to capillary endothelium and the placental syncytiotrophoblast 
(27). Most of the severe effects on maternal and neonatal outcomes are associated with P. 
falciparum infection, although some research has also assessed the adverse consequences of P. 
vivax infection (1). While P vivax found in peripheral blood of pregnant women has been 
associated with LBW, the magnitude of effect is not as great as with P. falciparum (1). It has 
been postulated that this reduced harmful effect is due to a lack of cytoadherence of P. vivax in 
the placental (1). However, more research is needed regarding the differential effects of malaria 
infection on adverse birth outcomes by Plasmodium species.  
 
Malaria prevention programs during pregnancy 
The knowledge that malaria infection during pregnancy induces negative maternal and 
fetal sequelae is not new, with research dating back to 1899 (30). The first trial aimed at 
preventing malaria during pregnancy using chemoprevention was in 1957, comparing monthly 
pyrimethamine to placebo (31). Since then, there have been over fifty trials assessing the 
effectiveness of various chemoprevention drugs, regimens, and strategies (31). The current WHO 
Policy Recommendations for malaria prevention during pregnancy involve three separate 
evidence-based strategies: insecticide treated bed nets (ITN), intermittent preventive therapy 
during pregnancy (IPTp), and effective case management (32). The current strategy for IPTp 
involves monthly doses of sulfadoxine/pryimethamine (SP) starting in the second trimester (32). 
However, the IPTp regimen was only recently changed in 2007, when monthly IPTp-SP replaced 
the prior WHO recommended IPTp schedule of one curative dose of SP in the second trimester 
and then a second dose in the third trimester (with a third dose recommended for HIV-infected 
women) (33). The recommendation change in 2007 which increased the dosage to monthly doses 
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was spurred by a meta-analysis showing added benefit of additional doses (34). An updated 2014 
Cochrane Review summarized data from eight randomized and quasi-randomized trials that 
effective chemoprevention of malaria with chloroquine prophylaxis or IPT reduced the risk of 
LBW by 27% (RR 0.73, 95% CI 0.61 to 0.87) in primi- and secundigravid women (31). This 
evidence is consistent with other observational and trial data (9,35,36). Another malaria 
prevention strategy, replacing IPTp- with intermittent screening for malaria infection (ISTp) at 
ANC visits using rapid diagnostic tests (RDTs) and treating infected women with 
dihydroartemisin-piperaquine, is currently being investigated(37,38). However, analyses from 
these ISTp studies suggest that ISTp is not a good alternative to IPTp (37). 
Despite an increase in the proportion of women receiving IPTp, the level of coverage 
remains inadequate (39–41). In 2013, an estimated 43% of the 35 million eligible pregnant 
women did not receive even a single dose of IPTp (41). Emerging parasitic resistance to 
important antimalarial medications, and particularly multi-drug resistance, presents another 
major concern for malaria prevention and treatment during pregnancy (42). The risk of infection 
in between IPTp doses may still be high, particularly in areas of low ITN usage and high 
sulphadoxine-pryimethamine resistance (28). In light of these limitations to malaria prevention 
during pregnancy, there is a need to explore alternative approaches to improving pregnancy 
outcomes, particularly in areas where malaria is endemic (43). 
 
Malnutrition during pregnancy 
Extent and impact of malnutrition during pregnancy 
Another modifiable risk factor for impaired fetal growth and subsequent LBW is 
maternal malnutrition (44,45). The prevalence of low body mass index (BMI), a marker of 
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malnutrition, reaches as high as 20% among African women of reproductive age (17,46). 
Malnutrition is a heterogeneous condition dependent upon macronutrient deficiency 
(carbohydrates, fats, proteins), micronutrient deficiencies (vitamins, minerals, trace elements, 
phytochemicals, and antioxidants), or both (46). The relationship between malnutrition and 
adverse birth outcomes is complex. Optimal fetal growth is dependent upon sufficient maternal  
dietary intake of macro- and micronutrients (particularly iron and folate) (44,47). However, 
micronutrient deficiencies are often difficult to measure in resource-limited settings, thus 
anthropometric measures of body composition are often assessed as approximate indicators of 
maternal malnutrition. Typical maternal anthropometric measures of malnutrition in resource-
limited settings are BMI or mid-upper-arm-circumference (MUAC). BMI and MUAC are 
indicators of maternal fat stores, which are reflective of maternal energy balance, and low values 
are a risk factor for poor pregnancy outcomes (17,44,48,49). Additionally, BMI and MUAC are 
correlated with maternal leptin levels, an adipose-tissue secreted protein, which may regulate 
fetal growth, although the effects of low levels of leptin remain unknown (50,51). Henceforth, 
we will use the term ‘malnutrition’ to indicate approximate nutrient deficiencies measured using 
anthropometric measures.  
A WHO collaborative study in 1996 reported an association between measures of 
maternal body size, such as height, weight, and BMI, and LBW, SGA, and preterm birth (48). A 
systematic review and meta-analysis in 2011 reported that underweight women have increased 
risks of preterm birth (aRR: 1.29 [95% CI: 1.15-1.46]) and LBW (aRR: 1.64 [95% CI: 1.38-
1.94]), although the definitions of underweight varied depending on the original study definitions 
(52). More recently, results from studies conducted in LMICs suggest that maternal malnutrition 
may be an independent risk factor for LBW and SGA. A 2015 study in Papua New Guinea 
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(PNG) found that maternal malnutrition, as measured by MUAC, negatively affected fetal 
growth (11).  Additionally, in the Democratic Republic of the Congo (DRC) low MUAC was 
associated with IUGR; in Thailand a low BMI was negatively associated with biparietal diameter 
z-scores in univariate analyses; and in Tanzania low MUAC was associated with lower infant 
anthropometric measurements (53–55). Due to the difficulties of accurately measuring 
malnutrition during pregnancy, some researchers have used pre-pregnancy anthropometrics as a 
proxy indicator of gestational malnutrition. A systematic review and meta-analysis of pre-
pregnancy anthropometrics found that pre-pregnancy underweight, compared with normal-
weight mothers, were at increased risk of SGA (OR: 1.81 [95% CI: 1.76-1.87) and LBW (OR: 
1.47 [95% CI: 1.27-1.71]) (56). Taken collectively, this information suggests that adequate 
maternal nutrition is integral for fetal health and development in LMICs (57).  
 
Malnutrition interventions during pregnancy 
Due to this association between maternal anthropometric measures and fetal development, 
a number of nutritional interventions targeted at pregnant women have been explored to optimize 
birth outcomes. Studies assessing actual dietary consumption have found that insufficient 
maternal protein intake is associated with LBW, especially in early pregnancy (44).  A meta-
analysis in 2011 summarized that balanced protein energy supplementation lead to a 31% 
relative reduction in the risk of SGA, and that this effect was even more pronounced among 
women malnourished at baseline (58). Most notably, a randomized control trial (RCT) in rural 
Gambia in the early 90s found that prenatal dietary supplementation targeting chronically 
undernourished pregnant women was associated with substantially lower odds of a LBW infant 
(OR=0.61 [95% CI: 0.47-0.79]) (59).   
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However, debate remains regarding whether dietary supplementation during pregnancy is 
beneficial overall and should be scaled up in LMICs.  Recently, two RCTS in Ghana and Malawi, 
as part of the International Lipid-Based Nutrient Supplements Project (iLiNS), assessed the 
effect of lipid-based nutrient supplements (LNS) for pregnant women on fetal growth. These two 
studies, with harmonized study designs, had contradictory results. In Ghana, but not in Malawi, 
prenatal LNS supplementation had a positive effect on fetal growth among first-time mothers 
(birth weight 237 grams greater in LNS arm among primigravid) (60).  
 
Malaria and malnutrition during pregnancy 
Background studies 
Recent evidence indicates that the relationship between malaria and LBW may depend 
upon the nutritional status of the mother (51). Two studies addressing the harmful effect of 
malaria on IUGR and subsequent LBW found a significant association between malaria and 
LBW among malnourished pregnant women, but no-to-minimal association among well-
nourished women (8,9), however two additional found inconsistent results (11). First, a small 
study published in 2009 of 177 Congolese women by Sarah Landis and colleagues showed that 
the risk of IUGR was two to eight times higher among women with evidence of malnutrition (8). 
In this study, the magnitude of the difference in effect sizes depended on the measurement for 
malnutrition (BMI vs MUAC vs short stature vs weight gain) and the measurement for malaria 
(cross-sectional versus cumulative); however, with all measurements of malnutrition and malaria 
the pattern and directionality of the modification was consistent. In a second study of 477 
Kenyan pregnant women published by Elizabeth McClure and colleagues in 2014, there was no 
statistically significant association between malaria and birth weight among pregnant women 
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with normal BMI, but among those with low BMI the mean difference in birth weight associated 
with malaria infection was -370 g (95% CI: -728, -12) (9). However, there could have been 
potential publication bias in these studies if they did not report findings when there was a lack of 
modification or interaction.  
A third cohort study published by Holger Unger and colleagues among Papua New 
Guinean women found contrary results. In this study, there was no modification of the effect of 
peripheral malaria on SGA by maternal anthropometric measures (N=671) (11). However, a 
subsequent unpublished analysis by the same group did find modification such that that the risk 
of LBW associated with active placental infection was highest among women with low BMI 
(Holger Unger, personal communication, June 15, 2015). However, modification went in the 
other direction when using MUAC (risk of LBW due to placental malaria was increased among 
women with normal MUAC and not among undernourished women). In a fourth study in Benin, 
the effect of malaria infection on fetal growth velocity was greatest among women with low 
anthropometric status, but there was no modification of the effect of malaria infection on 
birthweight z-scores (N=735) (12). Collectively, these studies suggest that there may be a 
synergistic relationship between malnutrition and malaria with regards to the risk of LBW, but 
further investigation is warranted. 
 
The biologic rationale surrounding malaria, malnutrition, and low birthweight 
The interplay between malaria and malnutrition with regards to LBW is supported by 
well-defined biologic rationale. The adverse intrauterine environment caused by malaria 
infection restricts sufficient placental delivery of nutrients to the fetus (2). P falciparum 
expresses a pregnancy-specific antigen variant, VAR2CSA, which enables the sequestration of 
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malaria-infected erythrocytes in the placenta (28). P falciparum infected red blood cells adhere 
predominately to the molecule chondroitin sulphate A in the intervillous area of the placenta (27). 
While P vivax has not been found to adhere to the placenta, it is still associated with increased 
placental inflammation and altered placental function (2,27). It is hypothesized that malaria-
infected red blood cells and inflammatory products obstruct the placenta, alter uterine vascular 
function, and cause dysregulation of pregnancy-associated growth-regulating hormones (2,3,61). 
These sequelae of malaria infection can cause both IUGR and preterm birth (27). Furthermore, 
malaria can also cause anemia, which itself can have deleterious effects on fetal development (2).  
While IUGR and preterm birth may both result from infection, they may also result from 
limited availability of maternal nutrients (4). Maternal nutritional status influences the 
availability and supply of nutrients to the developing fetus (62). Malaria and malnutrition may 
act along similar physiological pathways by decreasing maternal-fetal oxygen and nutrient 
transfer  and reducing uteroplacental blood flow, interfering with optimal fetal growth (2,4). The 
preliminary findings from the above-mentioned epidemiologic studies are thus further supported 
through research on the biologic mechanisms causing adverse birth outcomes. However, it still 
remains necessary to corroborate these findings with larger, robust, epidemiologic analysis. 
Further evidence of true synergism could provide  insight into the pathogenesis of malaria in 
pregnancy. 
 
Overview, limitations of the current evidence 
The major limitation of prior work is that it comes from only three small cohorts from 
three countries, with two studies reporting a strong synergistic interaction and the third reporting 
no interaction. Not only are these studies somewhat inconsistent in their findings, but our 
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confidence in their interpretation is hindered by their small sample size and potential lack of 
generalizability: none of the prior studies included HIV-infected pregnant women. The 
prevention and treatment of both malaria and HIV is complicated by immunologic, clinical, and 
therapeutic interactions between these two, potentially highly prevalent, infections (63). HIV-
infected women represent an important group to assess the interaction between malaria and 
malnutrition with regards to LBW.  
A potential synergistic relationship between malaria and malnutrition could have important 
implications for possible pregnancy interventions to improve fetal growth and prevent infant 
morbidity and mortality. Malnutrition, while highly prevalent in malaria-endemic countries, is 
modifiable and thus represents an ideal candidate for potential public health interventions, 
especially in early pregnancy. Mathematical modeling results assessing the effect of targeted 
ITN interventions and food supplementation for undernourished children suggests these targeted 
interventions could have substantial impact on malaria mortality and morbidity in children (64). 
However, assessments of hypothetical targeted interventions among pregnant women have not 
been addressed. Presently, over 20 million LBW infants annually are born (4). Improving our 
understanding of the joint effects of nutrition and malaria would help tackle this overwhelming 
health issue from a new, and actionable, perspective.  
 
Aim 1: Exposure Question 
Specifically, in this dissertation I investigated the joint effects of malaria infection and 
malnutrition during pregnancy with regards to increasing the risk of LBW. This aim focuses on 
the etiologic interaction between these two risk factors for LBW, and I hypothesized that there 
will be a net increase in the average estimated risk of LBW associated with joint exposure to 
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malaria and malnutrition compared to the sum of the average risks for each exposure 
independently (synergism).  
 
Aim 2: Intervention Question 
Furthermore, the main decision that public health officials may need to make is whether 
implementing or scaling up nutritional and antimalarial interventions during pregnancy can have 
a substantial public health impact on pregnancy outcomes in malaria-endemic countries. 
Specifically, in this dissertation I investigated the impact of implementing targeted antimalarial 
and nutritional interventions on population-level pregnancy outcomes. To accomplish this aim, I 
simulated several hypothetical interventions using the parametric g-formula.  
 
Interventional estimates 
State-of-the-art epidemiologic methods allow us to use complex, real-world data to 
estimate the effects of plausible public health interventions (13). Combining nutritional 
interventions with antimalarial interventions or targeting antimalarial interventions to 
malnourished women to reduce the risk of LBW has not been assessed (2), but could be highly 
effective and impactful for reducing fetal morbidity and mortality (1). To our knowledge, no one 
has calculated and reported interventional effect estimates for the impact of hypothetical 
malnutrition interventions in the context of malaria prevention programs or hypothetical targeted 
antimalarial interventions on LBW. Additionally, no one has calculated interventional effects for 
the expansion of existing antimalarial interventions, such as intermittent prophylaxis therapy 
during pregnancy (IPTp).   
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Calculation of interventional effects is rarely done in epidemiologic studies, despite the 
utility of such results (13,65). Most epidemiologic studies exclusively estimate the effects of 
specific exposures. However, these exposure effect estimates may be less valuable for policy 
decision-makers when considering interventions or changes in clinical practice, protocols, or 
guidelines (13). Instead of merely providing the exposure (etiologic) effects of malnutrition and 
malaria with regards to their effect on LBW, we also provided estimates of the effect of potential 
public health interventions.  
Interventional estimates can be calculated from longitudinal data by stochastically 
simulating different intervention scenarios (13,14,66). We used an imputation-based causal 
inference method called the parametric g-formula (15,67) to estimate a range of population 
intervention effects of plausible nutritional and antimalarial interventions. Specifically we 
estimated a series of generalized intervention risk differences, comparing the risk under the 
observed distribution of maternal malnutrition and malaria to the risk under a hypothetical, 
counterfactual setting in which specific and evidence-based candidate interventions reduce the 
extent of maternal malnutrition and/or malaria (13–15,66,67). The g-formula can be used to 
impute the missing outcomes under the unobserved, counterfactual exposure distribution that 
might be expected under the proposed interventions. We likewise compared the observed 
distribution of IPTp receipt and dosage to a counterfactual population in which these existing 
interventions are scaled-up.  
 
Policy and public health implications 
Provision of interventional effects in addition to exposures effects provides results that 
may be more immediately useful to policy-makers. For example, outputs from this work could be 
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directly used in cost-effectiveness models created by health policy professionals for 
understanding the impact of implementing potential joint interventions on malaria and 
malnutrition, integrating malnutrition interventions with existing malaria prevention programs, 
or targeting antimalarial interventions towards women with evidence of malnutrition. Risk 
factors for, and interventions to prevent, LBW are commonly studied in isolation and without 
cross-discipline collaboration. The interventional effects could provide valuable information to 
policy markers regarding the scale-up of both malaria prevention and malnutrition interventions 
during pregnancy.  
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CHAPTER III: RESEARCH METHODS 
Approach: Pooled Analysis 
Overview 
We conducted a pooled analysis of thirteen pregnancy studies conducted in malaria-
endemic settings to assess the interaction between malaria infection and maternal nutritional 
status during pregnancy in causing LBW. Secondly, we used advanced epidemiologic methods to 
further analyze the pooled data and provide interventional effect estimates translatable for policy 
implementation. We stochastically simulate different intervention scenarios using the parametric 
g-formula to estimate the impact of plausible targeted antimalarial and malnutrition interventions 
on LBW.  
Pooled data overview-study population 
The data for this work came from the Maternal Malaria and Malnutrition (M3) initiative 
(68). The M3 initiative comprised thirteen cohort studies and RCTs conducted among pregnant 
women in malaria-endemic countries. Studies were selected for M3 based on the availability of a 
predetermined set of essential variables for each woman, adequate ethical institutional review 
board (IRB) clearance for this secondary analysis, and willingness of collaborators to share data. 
Essential variables included the assessment of malariometric indices at enrollment/first antenatal 
visit, assessment of anthropometric indicators of nutritional status at enrollment (MUAC and/or 
BMI), gravidity, type of malaria prevention used, and age. Essential delivery outcomes included 
birthweight and sex. With birthweight being the primary focus, we opted to restrict inclusion to 
women who delivered live singleton infants without congenital abnormalities, as recommended 
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by Rijken et al. (69). Miscarriages and stillbirths were included in the shared data from four 
studies for sensitivity analyses (see page 127) (37).  
We identified 14,633 women who had singleton live births with no congenital 
abnormalities and participated in one of thirteen M3 pregnancy studies (Table 3.1). In total, 
seven RCTs and six prospective cohort studies performed from 1996 to 2015 in Sub-Saharan 
Africa (eight countries) and the Western Pacific (PNG) were included (Table 3.1, Figure 3.1). 
Included studies had initially been conducted with a range of objectives. Of the seven 
RCTs, four (37,38,70,71) assessed the effectiveness of different pharmacological malaria 
prevention regimens, one additionally evaluated nutritional supplementation (72), one was 
designed to solely assess the effectiveness of nutritional supplementation (60), and one measured 
the impact of ITNs on birthweight (73). Details of antimalarials and nutritional supplementation 
in these studies can be found in Table 3.1. Most women had hemoglobin measurements done at 
first antenatal visits, and most received routine iron/folate supplements, although information on 
iron/folate supplements was not collected for most studies. 
For ten of the thirteen studies, pregnant women were identified and recruited at one of 
their self-initiated antenatal care visits, usually the booking visit (8,60,70,71,74–76) but 
sometimes at a subsequent visit (77). The EMEP study enrolled women early in pregnancy, but a 
subset of these same women were also enrolled in a cross-sectional study at delivery, the IPTp-
MON study (78,79). The remaining two studies comprised slightly different study populations 
due to broader enrollment efforts (72,73). The Asembo Bay/ITN cohort (Kenya) identified 
pregnant women through monthly community census, and the FSP/MISAME study recruited 
through a community-based network of home visitors (72,73). Three studies excluded HIV-
infected pregnant women (37,60,80), three studies did not assess HIV status  (70,72,74), and the 
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remaining seven studies included both HIV-infected and HIV-negative pregnant women 
(8,71,73,75–79). 
 
Locations 
The thirteen studies covered seven countries in Africa and one in the Western Pacific 
(Figure 3.1, Table 3.1). P. falciparum was the predominant malaria species observed in areas 
where included studies were conducted. The two PNG studies also reported P. vivax infections 
(70,74). Some studies detected P. ovale and P. malariae infections but prevalence was low. 
Studies not differentiating between species (n=4) were conducted in areas where P. falciparum is 
the principal malaria species, and P. vivax is thought to be largely absent. Eleven studies reported 
high and perennial malaria transmission in the study area during the study period,(8,37,71–80) 
while two studies reported medium to high perennial malaria transmission (60,70). 
 
Available data/measurements 
Women in all studies had at least two study visits, at enrollment (at a gestational age that 
varied both between and within studies, Table 3.1) and delivery, but the frequency of follow-up 
visits during pregnancy varied by study. Given logistical and computational intensity required in 
pooling longitudinal measures with vast amounts of heterogeneity in frequency and timing of 
measurements, only data at enrollment and at delivery were pooled from every study. To address 
this limitation of the data, six studies (STOPPAM-Tanzania, STOPPAM-Benin, ISTp-Malawi, 
PNG-IPTp, PNG-Sek, ISTp-Malawi, STOPMIP-Kenya) provided repeat malaria diagnostics 
throughout pregnancy, which was not part of the original data request for the M3 cohort initiative. 
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Table 3.2 and Table 3.3 present available enrollment and delivery measurements for each 
included cohort.  
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Outcome assessment 
Delivery weight (used to define LBW) 
The main outcome of interest for this work was birth weight. We hypothesized based on 
current understanding of the biologic processes of malnutrition and malaria infection that these 
factors influence both intrauterine growth and preterm birth in malaria-endemic settings (2,3,45). 
However, both IUGR and preterm birth are difficult to accurately assess in resource-limited 
settings. Intrauterine growth restriction is more challenging to measure than SGA or LBW, as it 
requires frequent ultrasounds throughout pregnancy. Only eight of the twelve studies used 
ultrasounds to assess gestational age (Table 3.3).Thus, given our confidence in the accuracy and 
availability of birth weight measurements, we have chosen LBW as our primary endpoint. While 
LBW is only a proxy for insufficient transfer of nutrients and does not differentiate between 
IUGR and preterm birth, the implications of this adverse birth outcome for subsequent risk of 
infant death and poor early life development support its use as the main outcome of interest for 
the purposes of this work. For consistency, we chose to use the historically defined dichotomous 
cut point of less than 2,500 grams. In addition to dichotomizing births at the 2,500 gram cutpoint, 
we also assessed mean birth weight as a continuous outcome (3,81).  
Since we did have gestational age based on ultrasound in nine out of the thirteen studies, 
we conducted a sub-analyses looking at small-for-gestational age as an additional outcome. We 
assessed SGA among a sub-group of the study population with reliable gestational age at 
delivery as a proxy for IUGR. We used the new INTERGROWTH-21st birth weight reference 
(25).  
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Exposure assessment 
Malaria infection 
Malaria infection at enrollment 
Upon enrollment into each study, malaria infection was diagnosed by examination of 
peripheral blood (82). Parasitemia was assessed using one or more of the three following 
approaches: light microscopic (LM) examination of a Giemsa-stained blood smear, polymerase 
chain reaction (PCR), and rapid diagnostic tests (RDTs) (Table 3.2). In all but two studies, 
malaria at enrollment was diagnosed by LM. In the FSP/MISAME study in Burkina Faso, LM 
was only performed if a woman presented with symptoms consistent of malaria, i.e. fever or 
history of fever (72). In the iLiNS Ghana study, malaria was diagnosed using an RDT (60).  
For LM, peripheral blood collected from the study participant was applied as a blood 
smear, stained, and examined using a microscope with a 100X oil immersion objective (83). 
Microscopy is a relatively inexpensive diagnostic tool, used to visually detect, differentiate, and 
quantify parasites (82). The quality control for microscopy readings varied by study. Three 
studies had two separate microscopists read the slides with discordant readings adjudicated by a 
third reader (70,74,75), two studies sent a 10% sample of slides to be assessed by a independent 
technician (8,72), two studies did not report whether or not quality control measures were 
conducted (37,38), and six studies performed no quality control measures (60,71,73,76–78). 
RDTs check for malaria antigen in serum and are increasingly used in malaria-endemic areas 
when microscopy might not be readily or feasibly available (82,84). While RDTS are quick and 
easy, the antigenic variation may cause false negative results (28). Sensitivity of PCR, a DNA-
based detection technique, is much higher than LM and RDTs, but the role of submicroscopic 
 24
infections detected by PCR alone in causing adverse outcomes has not been clearly determined 
(85). 
While there is some heterogeneity in diagnostics used for malaria infection at enrollment, 
the main source of variability comes from the timing of malaria infection. As reported in Table 
3.1, there was a wide range in gestational age of women at enrollment, both within the individual 
studies and between studies. While most studies enrolled women in the second trimester, there 
were women enrolled as early as four weeks gestation and as late as forty weeks gestation. Using 
one definition of ‘malaria infection at enrollment’ obscures the variability in timing of these 
measurements during pregnancy. Despite sparse data on the importance of timing of malaria 
infection during pregnancies, studies show that infections during all time points of pregnancy 
impair fetal growth, however the time period of most importance is uncertain (72,86–88). The 
evidence that malaria appears to be detrimental regardless of gestational age of infection gives 
support to our use of a composite exposure of malaria infection at enrollment.  
 
Malaria infection at delivery 
A majority of studies included in the pooled cohort tested for malaria infection at delivery. 
Some studies used the same peripheral blood diagnostics at delivery that were used at enrollment 
and described above, but some studies also sought to determine placental malaria infection at 
delivery (Table 3.3). Microscopic examination of a Giemsa-stained peripheral blood smear is the 
standard for malaria diagnosis among non-pregnant women (82), but may not capture placental 
infection. Specific adhesion of infected red blood cells to chondroitin sulfate A in the intervillous 
space of the placenta leads to sequestration of parasites in the placenta that may be absent or 
undetectable in peripheral blood (89). 
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Presence of malaria parasitemia in the placenta was assessed using LM of a placental 
blood smear, PCR, and/or placental histology (90). The diagnosis of malaria using placental 
histology is defined on the basis of presence of three features: infected erythrocytes, hemozoin in 
monocytes/macrophages, and hemozoin in fibrin deposits (91). Active placental infection 
diagnosed using histology is defined as presence of infected red blood cells, chronic placental 
infection is defined as detection of parasites in combination with hemozoin, and past infection is 
defined as placentas with hemozoin but no parasites (91). 
Placental histology is considered the reference standard for placental infection, but is 
often not feasible in low-resource, malaria-endemic settings. A meta-analysis reported a 
summary estimate of sensitivity for peripheral LM and placental LM compared to placental 
histology was only 44% and 54%, respectively (28). Both PCR and RDTs were reported to have 
higher sensitivities for placental malaria (28). However, while histology is typically considered 
the most accurate reference standard, one recent study suggested the use of PCR as a more valid 
reference (89). This study among Mozambican women reported that microscopy, placental 
histology, and RDT combined did not identify 60% of malaria infections detected by PCR (89).  
 
Definitions of malaria infection for analyses 
The heterogeneity in diagnostic tests used across the pooled studies and the timing of 
malaria infection measurements complicates the definition of malaria exposure. We considered 
two separate main definitions of malaria infection: 1) malaria infection at enrollment and 2) 
malaria infection at delivery.  
Because the FSP/MISAME study in Burkina Faso only performed LM at study 
enrollment if a woman presented with symptoms consistent with malaria, we excluded this study 
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from all analyses on malaria infection at enrollment (72). This study was only included when we 
were assessing malaria infection at delivery (which was routinely assessed) or malnutrition. All 
remaining twelve studies in M3 measured malaria infection at enrollment, using either LM, PCR, 
and/or RDT. At study enrollment, we defined malaria based on light microscopic (LM) 
examination of a Giemsa-stained peripheral blood smear or a rapid diagnostic test (RDT) for 
malaria antigen.(28) Given the uncertain impact of sub-microscopic infections on LBW and the 
variation in availability of polymerase chain reaction (PCR) diagnostics across studies, we 
excluded PCR results.(92) In sensitivity analyses, we explored definitions of malaria including 
PCR results, and ‘any malaria’, defined as a positive LM, RDT, or PCR at enrollment, delivery, 
or during pregnancy (in five studies with relevant data). 
For delivery measurements, we also considered multiple classifications of malaria 
infection. Unlike malaria diagnostics at enrollment, the availability of malaria diagnostics at 
delivery is more limited and differential by study (Table 3.4). First, we defined malaria infection 
at delivery as a positive result for peripheral LM, placental LM, and placental histology (both 
active, chronic, and past). We conducted a complete case analysis for the exposure of malaria 
infection at delivery, excluding observations with missing malaria diagnostics, since malaria 
diagnostics were not systematically obtained at delivery. In sensitivity analyses, we explored 
including PCR results in the definition of malaria infection at delivery (92).  
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Maternal malnutrition 
There are various methods for defining individual malnutrition, but in low-resource 
settings the most common anthropometric measures are mid-upper arm circumference (MUAC) 
or BMI. Included studies were required to have a measurement of either MUAC and/or BMI 
(height and weight) captured at a pregnant woman’s first antenatal care visit or study enrollment.  
 
MUAC 
Mid-upper arm circumference is measured as the circumference of the left upper arm, 
assessed at the mid-point between the elbow and the tip of the shoulder (93). MUAC is used as 
an indicator of maternal protein reserves, fat stores, and malnutrition more broadly. There is no 
global consensus on a threshold to define malnutrition (94), but a conservative cut-point of 
MUAC <23 cm has been recommended for pregnant women in African and Asian contexts, 
regardless of gestational age (93). MUAC is only associated with modest changes throughout 
pregnancy (49), making it a useful measure of malnutrition when accurate gestational ages are 
unknown. We used MUAC at enrollment as our primary measure of maternal malnutrition, 
categorizing women as malnourished if MUAC< 23 cm and as well-nourished otherwise. 
However, it should be noted that loss of fat stores in the third trimester of pregnancy and a 
subsequent decrease in MUAC represents the mobilization of maternal stores to support fetal 
growth. In late pregnancy, when enrollment occurred for some women, MUAC might be less 
indicative of maternal fat stores (95). Thus, we can not discount our dichotomous measure of 
MUAC<23cm misclassifying some women as malnourished that might actually be having 
appropriate mobilization of fat stores. MUAC was measured in ten of the thirteen studies, which 
included 61% of our total study population (Table 3.5). For our main analysis, we multiply 
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imputed the missing MUAC for the two studies that were missing less than 20% of MUAC 
observations and we exclude the three studies that did not measure MUAC (96).  
 
BMI 
Weight and height measurements, which constitute BMI, were measured in addition to MUAC in 
nine of the main thirteen studies, were the sole measures of malnutrition in three studies, and one 
study did not collect height information (Table 3.5). In addition to defining malnutrition using 
MUAC, we also explored using BMI as the primary exposure measurement of malnutrition. 
There is not an exact one-to-one correlation between BMI and MUAC, thus cut-points using 
either of these exposures classify different women as well-nourished versus malnourished (94). 
However, according to the WHO, a pre-pregnancy BMI of <18.5 is a worldwide cut-point for 
malnutrition, and has been predictive of adverse birth outcomes (97). Low BMI is representative 
of wasting of lean and fat tissue. Thus, we were interested in looking at BMI as a measurement 
of malnutrition in addition to MUAC. Both are imprecise proxies for maternal malnutrition, but 
it is valuable to know which measure is of more importance when assessing the interaction 
between malaria infection and malnutrition.  
 BMI during pregnancy encompasses gestational weight gain, thus is a poor measure of 
maternal malnutrition after the first trimester (48).  Despite the caution that there is insufficient 
evidence for a cut-point for BMI by gestational age in developing countries (93), previous work 
on this topic has used cut-points for low BMI (8,9). In a study by Landis and colleagues in the 
Democratic Republic of the Congo on the interaction between malaria and malnutrition (low 
BMI or low MUAC) on LBW, low BMI was defined at enrollment (≤22 gestational weeks) as 
<19.8 kg/m2 (8). In a separate study by McClure and colleagues in Kenya on the interaction 
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between malaria and malnutrition (low BMI) on birth weight, low BMI was defined as below the 
10th percentile for gestational age at antenatal care visits (9). For this study population, the cut-
point for the 10th percentile of BMI ranged from 19.8 to 20.7 at the beginning of the second 
trimester and third trimester, respectively. However, given that we are pooling multiple studies 
with heterogeneous distributions of BMI, defining low BMI using a percentile cut point would 
obscure comparability between studies.  
While the WHO recommends a cut point of <18.5 for defining low BMI for 
prepregnancy BMI, there are no standard cut points for defining low BMI during the course of 
pregnancy. In most of the studies BMI was not recorded until time of study enrollment, which 
varied by study (Table 3.1). This complicates creating a precise cut point for BMI due to the 
changes in maternal physiology and additional weight of the fetus during pregnancy. We defined 
a low BMI as an imputed pre-pregnancy BMI <18.5 kg/m2. To impute pre-pregnancy BMI, we 
first regressed BMI on age, age squared, and age cubed and saved both the predicted value of 
BMI and the residual (actual BMI value minus predicted value). The mean BMI of the first 
trimester (proxy pre-pregnancy BMI) was then determined. Finally, the imputed pre-pregnancy 
BMI values for each woman were calculated as the mean BMI of the first trimester plus the 
individual residual value determined in the first step. This approach was taken by the iLiNS-
Dyad study team, whose statistical analysis plan is publically available (http://ilins.org/ilins-
project-research/data-analysis).  
In conclusion, we assessed two classifications of malnutrition: 1) MUAC <23 cm, 
regardless of gestational age; 2) imputed pre-pregnancy BMI <18.5 kg/m2. While no 
measurement is perfect, MUAC and BMI are easily measured in low resource settings and 
represent the best available data for assessing malnutrition in our pooled dataset.  
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Covariate assessment/definitions 
Additional covariates that are likely to be important in the current analysis and were 
assessed in at least some of the studies include maternal age, gravidity, gestational age at 
enrollment, gestational age at delivery, sex of infant, hemoglobin and/or hematocrit at enrollment, 
area of residence, implemented malaria prevention interventions for each study, and nutritional 
interventions for each study. Availability of each covariate by study is reported in Tables 3.2 and 
3.3.  
 
Maternal age 
Maternal age was ascertained through self-report for all women in all included studies. 
We used Akaike information criterion (AIC) to determine the best fit for control of maternal age 
using restricted cubic splines, linear splines, or quadratic, cubic, or linear transformations of 
maternal age (98).  
 
Gravidity 
 Gravidity was ascertained through self-report for all women in all included studies. We 
categorized gravidity as primigravid (gravidity=1), secundigravid (gravidity=2), and 
multigravida (gravidity ≥3).  
 
Gestational age at enrollment 
Gestational age at enrollment was ascertained using either US or SFH. Only 0.4% of the 
study population was missing gestational age by one of these measures. US measurements were 
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available for nine of the thirteen studies (Table 3.2). In the first two trimesters US is the gold 
standard for gestational age estimation, with waning accuracy in the third trimester (99).  SFH, 
plus or minus one to three centimeters, estimates gestational age beginning in the second 
trimester, although this does not take into account IUGR (100). When available, we used US 
measures for gestational age, otherwise we used SFH. 
 
Delivery gestational age 
Reliable gestational age at delivery using US were available for nine of the thirteen 
studies (Table 3.3).  
 
Sex of infant 
Information on the sex of the infant was ascertained for all women in the study 
population (Table 3.3). While sex of the infant is not a confounder, the sex of the infant was 
important for definition of the secondary outcome, SGA, which requires use of a gestational age 
and sex specific birth weight reference (25).   
 
Timing of birth weight 
Six of the twelve studies restricted their study population to infants that were weighed 
within 24 hours of delivery, and the remaining seven allowed for weighing within one week. In 
some of the studies the majority of women delivered at home, thus obtaining birth weight within 
24 hours was challenging. Allowing for inclusion of data on infants measured within one week 
increases the amount of available data. To account for typical infant weight loss within that first 
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week, we estimated birth weight using a cubic regression model, which was determined to be the 
best fit model based on AIC (101).  
 
Hemoglobin and hematocrit at enrollment 
Low hemoglobin and hematocrit are indicators for anemia (102). 98.2% of the study 
population had either a hemoglobin or hematocrit measure at enrollment (Table 3.2). 
Hemoglobin is an iron-rich protein in red blood cells that is responsible for delivery of oxygen to 
tissues and hematocrit is a measure of how much space red blood cells take up in the blood (102). 
We defined anemia as a hemoglobin < 11 g/dL of venous blood, if available, or hematocrit <33 
g/dL, in the first and third trimesters, and less than 10.5 and 32, respectively for the second 
trimester (103). Hemoglobin and hematocrit were measured at enrollment, thus the trimester of 
measurement varied by study (Table 3.1). 
 
Area of residence 
Whether women lived in a rural versus urban setting was recorded for >99% of the study 
population (Table 3.2). Five studies described their study population as all living in rural settings 
(71–73,78,88),  two studies were from urban settings (8,60), and six studies differentiated 
between those living in urban and rural residencies (37,38,70,74,76,77). However, the distinction 
between rural and urban was not systematically assessed, thus while this variable is available for 
all studies it may have slightly variable meanings in each context.  
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Malaria Prevention and Nutritional Supplementation during pregnancy 
Details of antimalarials and nutritional supplementation in these studies can be found in 
Table 3.1. Variables to indicate the malaria prevention policy for the region at the time for 
observational studies and what the malaria intervention arm was for RCTs were included in the 
M3 dataset. Information on how many doses of prophylaxis women actually received was 
available for six of the thirteen studies, and for the IPTp arms of the ISTp-Malawi and 
STOPMIP-Kenya studies. Self-reported bed net ownership at enrollment was also ascertained in 
eight out of the thirteen studies; 62% reported bed net ownership, which likely overestimates the 
usage of bed nets. 
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Table 3.1. Characteristics of the 13 individual studies included in the Maternal Malnutrition and Malaria (M3) 
Initiative.  
Countries Study Name Design Period Median 
GA 
(IQR)* 
Malaria 
prevention† 
Nutritional 
intervention 
N‡ n§ 
Benin STOPPAM I Cohort 2008-
2010 
 
17 (14-20) IPT-SP  None 1037 791 
BF FSP/MISAME RCT 2006-
2008 
16 (11-21) IPT-SP(2), 
IPT-SP(3)  
MMS, FFS 1296 1020 
DRC ECHO Cohort 2005-
2006 
 
19 (17-21) IPT-SP None 182 164 
Ghana iLiNS-DYAD RCT 2009-
2012 
 
17 (15-20) IPT-SP LNS, MMN, 
IFA  
1320 1068 
Kenya EMEP & 
IPTpMon 
Cohort # 2011-
2013 
23 (16-29) IPTp-SP None 1453 471# 
Kenya ITN RCT 1996-
1999 
24 (20-30) IPT-SP 
started during 
study  
None 911 711 
Kenya Kisumu cohort Cohort 1996-
2001 
36 (34-37) IPT-SP 
started during 
study 
None 3155 3388** 
Kenya STOPMIP RCT 2012-
2015 
23 (20-26) IPT-SP, IPT-
DHA-PQ, 
IST-DHA-PQ 
None 1546 1203 
Malawi ISTp RCT 2011-
2013 
 
21 (19-23) IPT-SP, IST-
DP 
None 1873 1601 
Malawi LAIS RCT 2003-
2006 
 
20 (18-23) IPT-SP(2), 
IPT-SP(4) 
IPT-SPAZ 
None 1320 1190 
PNG IPTp study RCT 2009-
2013 
 
22 (19-25) IPT-SPAZ; 
Single dose 
SP and 
weekly CQ  
None 2793 1943 
PNG Sek cohort  Cohort 2005-
2007 
 
25 (22-28) Single dose 
SP and 
weekly CQ  
None 470 293 
Tanzania STOPPAM II Cohort 2008-
2010 
 
19 (15-21) IPT-SP  None 995 789 
BF=Burkina Faso. CQ= chloroquine. DHA-PQ=Dihydroartemisinin-piperaquine. DRC=Democratic Republic of the Congo. 
FFS=fortified food supplementation. IFA=iron and folic acid supplementation. IPT (doses)=intermittent preventive treatment in 
pregnancy. IST=intermittent screening for malaria infection. LNS=lipid-based nutrient supplementation. MMS=multiple 
micronutrients supplementation. PNG=Papua New Guinea. RCT=randomised controlled trial. SP=sulphadoxine-pyrimethamine. 
SPAZ= SP and azithromycin.  
* Median (IQR): Gestational age at enrolment assessed by fetal biometry, or symphysis-pubis fundal height when ultrasound 
unavailable 
†If RCT, describes the intervention, if cohort, describes the national policy during the study period  
‡N=Enrolled in parent study. 
§ n=live birth pregnancies that met inclusion criteria for M3.  
# The EMEP study was a prospective cohort study with some overlapping enrolment with the cross-sectional study IPTp-MON. 
111 pregnancies were enrolled in both EMEP and IPTp- MON; information on malaria infection at delivery was obtained for the 
subset of women in IPTp-MON. 
**Includes additional women from a sub-study not included in the parent study which otherwise met inclusion criteria for the 
pooled data.   
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Figure 3.1. Geographical locations where the thirteen parent studies were conducted: Benin, Burkina Faso, 
Democratic Republic of the Congo, Ghana, Kenya, Malawi, Papua New Guinea, and Tanzania. 
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Table 3.2. Key measures at enrolment across the 13 studies included in the Maternal Malnutrition and Malaria (M3) Initiative.  
Variable STOPPAM
- Benin 
FSP/ 
MISAME
- BF 
ECHO
- DRC 
iLiNS-
DYAD-
Ghana 
EMEP& 
IPTpMon-
Kenya 
ITN- 
Kenya 
Kisumu
- Kenya 
STOPMIP
-Kenya 
ISTp-
Malawi 
LAIS-
Malawi 
IPTp-
PNG 
Sek-
PNG 
STOPPAM
-Tanzania 
Essential variables              
Malaria              
LM X X* X  X X X X X X X X X 
PCR        X X  X X  
RDT X†   X‡    X§ X§    X† 
Anthropometrics              
MUAC X* X X X  X*  X#  X X X X 
Weight X X X X X X X X X X X X X 
Height X X X X X X X X X X X  X 
Gravidity X X X X X X X X X X X X X 
Anaemia††              
Haemoglobin X X  X X X X X X X X X X 
Haematocrit   X           
Optional variables              
Gestational age              
Ultrasound X X X X X*    X X X*  X 
Fundal height X X* X X X* X X X X X X X X 
Age X X X X X X X X X X X X X 
Smoking (Y/N) X  X  X     X X X X 
HIV X  X X X X* X X X X   X 
Rural/urban area X  X X X X X X X X X X X 
Bed net ownership X  X   X  X X X X X X* 
Available information indicated with X, missing data >10% indicated by asterisk, and systematically missing data indicated with grey highlighting. BF=Burkina Faso. DRC=Democratic Republic of the 
Congo. HIV=human immunodeficiency virus. IPTp=intermittent preventive treatment in pregnancy. ISTp=intermittent screening for malaria infection in pregnancy. ITN=insecticide-treated bed nets. 
LM=light microscopy. MUAC=mid-upper arm circumference. PNG=Papua New Guinea. PRC=polymerase chain reaction. RDT=rapid diagnostic test. † The STOPPAM Benin and Tanzania studies 
primarily used the Parascreen RDT (Zephyr Biomedical Systems, Goa, India), which detects P. falciparum histidine protein-2 (HRP-2) and Plasmodium lactate dehydrogenase (pLDH). ‡ The iLiNS-
DYAD-Ghana study used the Clearview Malaria Combo RDT (British Biocell International Ltd., Dundee, United Kingdom), which detects HRP-2 and plasmodium  aldolase  § Women randomized to 
the ISTp arms of the STOPMIP-Kenya and ISTp-Malawi studies were tested with a First Response Malaria Ag. (pLDH/HRP2) Combo RDT (Premier Medical Corporation, India)  # Maternal MUAC 
measured at delivery †† Nine studies measured haemoglobin using a HemoCue haemoglobinometer (Hemocue, Angelholm, Sweden),20–22,26–31 one study relied on haemoglobin measures from a local 
laboratory (unknown make),23 one study used Sysmex hematological analyzer (Kobe, Japan),32 and one study collected capillary blood (finger stick) specimens for determination of haematocrit or 
haemoglobin levels using a standardised chart.10 In the ITN-Kenya study, haemoglobin was measured using a HemoCue haemoglobinometer (Hemocue, Angelholm, Sweden) before 1997, and from 
1997 onwards capillary blood (finger stick) specimens were collected for determination of haematocrit levels, which were divided by a factor of three and presented as haemoglobin values for 
consistency with the 1996 data.  
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Table 3.3. Key measures at delivery across the 13 studies included in the Maternal Malnutrition and Malaria (M3) Initiative.  
Variable STOPPAM
- Benin 
FSP/ 
MISAME
- BF 
ECHO
- DRC 
iLiNS-
DYAD-
Ghana 
EMEP& 
IPTpMon-
Kenya 
ITN- 
Kenya 
Kisumu
- Kenya 
STOPMIP
-Kenya 
ISTp-
Malawi 
LAIS-
Malawi 
IPTp-
PNG 
Sek-
PNG 
STOPPAM
-Tanzania 
Essential variables              
Malaria- peripheral              
LM X* X* X  X*† X X X X X* X X X 
PCR          X* X X  
Malaria-placental              
LM X* X*   X*† X X X X  X* X* X* 
PCR        X X  X* X* X* 
Histology   X     X X  X* X*  
IPTp doses 
received 
X X* X  X   X X* X X  X 
Birthweight X X X X X X X X X X X X X 
Infant sex X X X X X X X X X X X X X 
Optional variables              
Gestational age              
By ultrasound X X X X X*    X X X*  X 
Neonatal 
measurements 
             
Abdomen 
circumference 
X*  X        X  X 
Chest 
circumference 
 X        X    
Head 
circumference 
X X X X X   X X X X X X 
Crown heel length  X X X X X  X   X X  
Timing of 
measurements 
X  X X X X X X X X X X X 
Available information indicated with X, missing data >10% indicated by asterisk, and systematically missing data indicated with grey highlighting. 
BF=Burkina Faso. DRC=Democratic Republic of the Congo. IPTp=intermittent preventive treatment in pregnancy. ISTp=intermittent screening for malaria infection in pregnancy. ITN=insecticide-
treated bed nets. LM=light microscopy. PNG=Papua New Guinea. PRC=polymerase chain reaction  
† For the EMEP/IPTpMON study, only women co-enrolled in the IPTpMON study (n=111) had malaria diagnostics at delivery. 
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Table 3.4. Percentage of study population for which various diagnostics of malaria at delivery were measured. . 
Study Name Countries N Peripheral Placental Missing any 
malaria 
measurement at 
delivery 
   LM PCR LM PCR Histology  
Sek cohort  PNG 293 100 % 94 % 78 % 74 % 76 % 0 % 
IPTp study PNG 1943 98 % 97 % 81 % 65 % 71 % 1 % 
iLiNS Ghana 1068 - - - - - 100 % 
ISTp Malawi 1602 96 % - 97 % 90 % 93 % 2 % 
STOPMIP Kenya 1546 99% - 97 % 95% 97% 1% 
STOPPAM I Benin 791 75 % - 70 % -   20 % 
STOPPAM II Tanzania 789 97 % - 46 % - - 2 % 
LAIS Malawi 1190 38 % 38% - - - 62 % 
Kisumu cohort Kenya 3388 90 % - 98 % - - 1 % 
Asembo Bay, ITN Kenya 711 92 % - 90 % -  - 8 % 
EMEP& IPTpMon  Kenya 471 24% - 23% - - 76%* 
FSP/MISAME Burkina Faso 1020 70% - - - - 30% 
ECHO DRC 164 100 % - - - 100 % 0 % 
PNG=Papua New Guinea. DRC=Democratic Republic of the Congo. BF=Burkina Faso. IPTp=intermittent preventive treatment 
in pregnancy. ISTp=intermittent screening for malaria infection in pregnancy.* The EMEP study was a prospective cohort study 
with some overlapping enrolment with the cross-sectional study IPTp-MON. 111 pregnancies were enrolled in both EMEP and 
IPTp- MON; information on malaria infection at delivery was obtained for the subset of women in IPTp-MON 
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Table 3.5. Percent of observations with measured mid-upper arm circumference (MUAC) and body mass index 
(BMI). Also reported is the range in gestational age of anthropometric measurement at enrollment. 
Study Name N MUAC BMI GA (wks)*  
Sek study, PNG 293 100 % 0 % 8-35 
IPTp study, PNG 1943 100 % 100 % 6-33 
iLiNS, Ghana 1068 100 % 100 % 7-39 
ISTp, Malawi 1590 0% 100 % 14-30 
STOPMIP Kenya 1203 100% (delivery) 100% 8-36 
STOPPAM I, Benin 791 88% 100 % 4-29 
STOPPAM II, Tanzania 789 100 % 100 % 6-24 
LAIS, Malawi 1190 100 % 100 % 14-26 
Kisumu, Kenya 3388 0 % 100 % 30-40 
ITNs study, Kenya 711 87% 100 % 4-40 
EMEP&IPTpMON, Kenya 471 0% 100% 4-41 
ECHO study, DRC 164 100 % 100 % 10-22 
FSP/MISAME, BF 1034 100 % 100 % 4-38 
*Range in gestational age at enrollment as measured by symphysis-pubis fundal height or ultrasound 
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CHAPTER IV: ANALYTIC METHODS 
 
Analytic approach for aim 1 
Aim 1: To investigate the joint effects of malaria infection and maternal malnutrition during 
pregnancy on the risk of LBW.  
Hypothesis: We hypothesized that there would be a synergistic interaction between malaria 
infection and malnutrition in causing LBW, such that the observed joint effect of being both 
infected with malaria and malnourished would be greater than expected if considering each 
exposure independently. 
 
Pooled analysis 
Since we pooled individual-level data from thirteen separate studies, we needed to 
account for variation in the estimate effects across studies due to differences in patient 
populations, study procedures, study location and calendar time (104,105). There are two 
commonly employed approaches for handling individual pooled data, a one-step approach and a 
two-step approach, although there is no consensus as to which approach is preferable 
(104,106,107). The one-stage approach analyzes all of the data simultaneously but accounting 
for clustering among patients in the same study using separate intercepts for each study (fixed 
effect) or random effects for intercepts and slopes. A two-stage approach analyzes each study 
separately and then combines summary estimates using standard meta-analytic techniques 
(104,107). Comparisons of one and two-stage approaches based on examples, theory, and 
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simulation studies indicate similar results between the two approaches (104–108). However, 
two-stage approaches are generally considered more easily interpretable, and allow the 
investigator to visually present forest plots and quantify statistical heterogeneity (106). Thus, we 
employed a two-stage approach, analyzing each study separately and then pooling summary 
estimates using standard meta-analytic techniques. As a secondary analysis, we also examined 
the consistency of results with a one-stage approach, fitting a generalized mixed model with 
random intercept and slope effects.  
For stage one of the two-stage approach, study-specific effect estimates were calculated 
using linear and log binomial regression models controlling for a minimally sufficient set of 
confounders identified through the evaluation of a directed acyclic graphic (DAG, See Section 
4.1.2) through inverse probability of treatment weighting (IPTW, See Section 4.1.2). In the 
second stage, effect estimates and interaction statistics (Section 4.1.3) were pooled using 
random-effects models (108). For the random effects model we used the restricted maximum 
likelihood method of DerSimonian and Laird to obtain mean and variance () of random effects 
distributions (109). This random effects model assumes that the true effects among the different 
studies are drawn from a normal distribution (109).  The estimated mean is a weighted average 
of the estimates from each individual study with weights inversely proportional to the total 
variance of each estimate (109). When study variance () was greater than zero we calculated 
95% population effects intervals (PEI) (110,111). The 95% PEI is the range within which 95% of 
the different study populations’ effects are estimated to lie within. We assessed the influence of 
study characteristics on the heterogeneity of effect estimates using meta-regression. We decided 
a priori to evaluate modification of the results by time period (before versus after 2008) due to 
changes in antimalarial recommendations, study type (trial/cohort), location (Africa/Western 
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Pacific), and malaria infection prevalence (based on M3 data). The separation between studies 
done before 2008 is to distinguish between studies conducted before and after the change in IPTp 
recommendations.  
While these approaches follow the methodology of individual patient-level meta-analyses 
(IPD-MA), this project did not involve the systematic ascertainment of studies from a systematic 
review, thus we refrained from using the terminology “meta-analysis” (108). While we have no 
reason to believe that the obtained studies in M3 are different from studies not included, we 
cannot discount the possibility that these studies may not be a random sample of all available 
data and could potentially result in selection bias.  
 
Directed acyclic graph (DAG) 
Confounders were identified using the directed acyclic graph (DAG) in Figure 4.1. 
Measured confounders common for all analyses include maternal age, gravidity, area of 
residence, and HIV infection. When assessing malaria at delivery instead of malaria at 
enrollment, additional confounders include the number of doses of IPTp received during 
pregnancy and anemia at enrollment. Potential unmeasured confounders include helminth 
infections, and other micronutrient deficiencies, particularly iron deficiency.  
Notably, when considering the exposure of malaria infection at enrollment, anemia at 
enrollment is a mediator, thus should not be included in the multivariable model. Malaria 
infection contributes to anemia through both increased removal of red blood cells by the host 
immune system and decreased production of red blood cells in the bone marrow (112). When the 
exposure is malaria infection at delivery, anemia at enrollment is a confounder and should be 
included in the model. However, when considering the interaction between malaria at enrollment 
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and malnutrition at enrollment, anemia is a mediator between malaria and LBW but a 
confounder between malnutrition and LBW (Figure 4.1).  
We cannot control for confounding through traditional multivariable regression due to the 
relationship between anemia at enrollment, malaria at enrollment, malnutrition at enrollment, and 
LBW. However, by using inverse-probability of treatment weighted (IPTW) marginal structural 
models (MSM), we can circumvent this problem (113). IPTW-MSM control for confounding by 
modeling the relationship between the exposures of interest and the confounding variables. We 
created separate treatment weights for malaria and malnutrition, which enabled the inclusion of 
anemia in the weights for malnutrition but not for malaria at enrollment.  
 
Assessment of interaction 
We estimated associations between malaria infection and malnutrition and the outcome 
of LBW using log binomial and linear regressions. Using log binomial regression we estimated 
risk ratios and using the linear regression model we estimated differences in mean birthweight 
separately for each study. Specifically, we modeled the probability of LBW or mean birthweight 
with respect to the two exposures of interest, malaria infection and malnutrition, the interaction 
between these two variables (coded as a product term between these two variables in the model), 
and used the inverse-probability of treatment weights to control for confounding. The inclusion 
of the interaction term in the model allows for the estimates for malaria infection versus no 
malaria infection to be heterogeneous across strata of malnutrition, and vice versa for the effect 
of malnourished versus well-nourished across strata of malaria infection. There are four possible 
combinations of the two exposures: malaria-uninfected/well-nourished, malaria-
uninfected/malnourished, malaria-infected/well-nourished, and malaria-infected/malnourished. 
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This approach allows us to consider malnutrition as a co-primary exposure, along with malaria 
infection, instead of just as a modifier of the malaria and LBW relationship. Epidemiologists 
often use effect measure modification and interaction synonymously, but there is a nuanced 
distinction between these two concepts (114). In this work, we were specifically interested in the 
interaction between malaria infection and malnutrition, since both exposures are modifiable and 
we have confounders measured for both exposures relative to the risk of LBW. Specifically, we 
were not only interested in how malnutrition modifies the relationship between malaria infection 
and LBW as suggested by prior studies, but were more precisely interested in the joint effects of 
both malaria and malnutrition on LBW. Interaction is valuable in addition to looking at effect 
measure modification because we could potentially intervene on both malaria and malnutrition.  
We assessed interaction on both the multiplicative and additive scales, however, it has 
been argued that the additive scale is more applicable for public health (115). We calculated an 
estimate of the interaction contrast (IC), which is a measure of the difference between the 
observed risk for women jointly exposed to being both infected with malaria and malnourished 
and the expected risk for women jointly exposed under the assumption of additive risks (no 
interaction). An IC greater than zero indicates a net increase in the positive, harmful association 
of malaria with joint exposure to malnutrition. We calculated IC statistics and multiplicative 
product terms separately for each study and then pooled across studies to obtain an overall IC 
and overall multiplicative product term (See Section 4.1.1).  
 
Analytic approach for aim 2 
Aim 2. To explore the impact of hypothetical targeted antimalarial and nutrition interventions on 
population-level pregnancy outcomes.  
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Implementation of the g-formula 
There are the four steps to estimating interventional estimates.(14,66) 
1) First, we modeled the association between the exposure(s) (malaria, malnutrition, ITN 
ownership, IPTp dosage) we hope to modify and the outcome, LBW. We used logistic regression 
models, controlling for known and measured confounders, and generalized estimating equations 
to account for within-study correlation. Confounders for the relationship between malaria 
infection at delivery and LBW were determined from a causal directed acyclic graph (DAG) 
(116) based on prior literature on the relationship between covariates, and included study site, 
maternal age, gravidity, rural versus urban residence, HIV infection, anemia at enrollment, and 
the number of IPTp doses. Confounders for the malnutrition-LBW relationship were obtained 
from a separate DAG and included study site, maternal age, gravidity, rural versus urban 
residence, anemia at enrollment, and HIV infection. Study site was the only measured 
confounder for the bed net coverage-LBW relationship and study site and HIV infection were the 
only measured confounders for the IPTp-LBW relationship.   
2) Second, we “set” the exposure (malaria, malnutrition, ITN ownership, IPTp use) to the 
level specified for the particular hypothesized intervention (See Sections 4.2.2-4.2.4). With this 
exposure “set”, we imputed the probability of having a LBW infant for each mother. 
3) Third, we averaged the imputed probabilities for LBW across the population, for each 
“set” level of exposure. Comparison of the average outcomes for the different “set” exposures 
provides us with population-wide predicted effect of changing exposure on the prevalence of 
LBW in the whole population, the population-standardized risk difference. We also estimated the 
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number needed to treat (NNT) for each contrast of “set” exposures. The NNT is calculated as the 
reciprocal of the absolute value of the risk difference.   
4) We calculated confidence intervals using non-parametric bootstrapping techniques (200 
samples with replacement from original dataset) (117).  
 
Interventional Estimates: Overview 
In epidemiology, we typically assess the etiologic causal question regarding the effect of 
one or more exposures on a particular outcome. To assess this question, we use analytic tools 
(regression analyses or g-methods) to ask what the risk of the outcome is if the population had all 
been exposed versus none of the population had been exposed, known as the population average 
causal effect (118). Assuming the circles in Table 4.1 illustrate the factual or counterfactual 
study population, where the black portion is representative of the exposure prevalence, then 
scenario 1 illustrates a contrast between the risk when the whole population is exposed and the 
risk when no one is exposed; we refer to this as the average causal effect. Note, the circles in 
Table 4.1 do not illustrate the expected risk of LBW, rather they exclusively focus on the 
exposure distribution among the study population. 
Aim 1 of this work focuses on the etiologic synergistic effects of maternal malnutrition 
and malaria infection on LBW. Questions regarding the etiologic effect of malaria and 
malnutrition would be: 1) what if everyone in the population had malaria compared to none, 2) 
what if everyone in the population were malnourished compared to none, and 3) what if 
everyone in the population had both malaria and malnutrition, compared to neither (and 
compared to just malaria or malnutrition independently).  
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However, understanding the implications of implementing realistic interventions on 
malaria and malnutrition for population-level birth outcomes is equally, if not more, informative 
for public health policy decisions. We used an imputation-based causal inference method called 
the parametric g-formula(15,67) to stochastically simulate seven different intervention scenarios 
(13–15). The different intervention scenarios were modeled are as follows: 
 
Malaria interventions 
The malaria interventions to be assessed intervene on the following four exposures: 
malaria infection at delivery, ITN ownership at enrollment, and receipt of intermittent preventive 
therapy during pregnancy (IPTp). 
Interventions specific to malaria infection at delivery 
For malaria infection at delivery, we calculated population attributable contrasts, which 
compares the observed distribution of malaria to the population had no women been infected 
with malaria (Table 4.1, scenario 2). However, this intervention contrast only assesses a 
hypothetical intervention with non-specific mechanisms of prevention. While this contrast does 
not guide policies for direct interventions during pregnancy, it does highlight the potential impact 
of increased ITN coverage in women of reproductive age.   
Bed net ownership and IPTp use during pregnancy 
To better guide policies for specific evidence-based interventions, we also assessed the 
impact of scaling up existing malaria prevention efforts implemented in the pooled studies, 
specifically bed net ownership at enrollment and IPTp prophylaxis during pregnancy. Unlike the 
prior contrasts where we were looking at removal of malaria, now we are specifically looking at 
scale-up of malaria prevention strategies.  In our pooled data, among women with available self-
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reported information on bed net ownership, 62% reported owning a bed net at enrollment. Even 
though this variable is likely an overestimation of actual bed net use (40), we can use this 
information for an intention to treat (ITT) analysis of the ownership of bed nets under typical 
usage.  Again, we calculated a population attributable contrast, comparing the observed 
distribution of bed net ownership at enrollment to the population had all women owned bed nets 
enrollment (Table 4.1, scenario 3). 
 Another existing malaria prevention strategy is IPTp prophylaxis during pregnancy. We 
had information on what antimalarial interventions were the national public health policy, which 
drugs were assigned (if an RCT), and how many doses of prophylaxis were received before 
delivery. Of the 14,633 women in M3,  1,148 (8%) lack data on how many doses of IPT they 
received and were excluded for this interventional estimate. Of the remaining 13,485 women, 
39% received no IPTp doses, 15% received only one dose of IPT, 18% received only two doses 
(the recommended schedule prior to 2007), and 28% received three or more doses (similar to the 
monthly schedule recommended since 2007) (Figure 9f). 
First, we only intervened among those who received less than two doses of IPTp and ‘set’ 
(simulate) their exposure to be 2 doses. This allowed us to estimate a generalized intervention 
contrast, comparing the observed distribution of IPTp receipt to the population where everyone 
has two or three doses of IPTp (Table 4.1, scenario 4a). Second, we simulate everyone receiving 
three+ doses (similar to the monthly schedule recommended since 2007) (Table 4.1, scenario 4b). 
Given that the national target for many of the malaria-endemic countries represented by our 
study population is 80% coverage, we also assessed increasing the dosage to at least three doses 
of IPTp in 80% of the study population (40).These interventional estimates informed on the 
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population level impact that scaling up IPTp could have in malaria endemic settings. However, 
this approach does not take into account drug type differences or regional drug resistance.  
 
Malnutrition interventions 
Next, we considered a hypothetical intervention on maternal malnutrition . We took a 
similar approach to this exposure as we did to malaria, first comparing the risk of LBW if the 
population of women all had MUAC below 23 cm (all-shaded circle) versus if all of the women 
had MUAC at or above 23 cm (unshaded circle), and then comparing the observed distribution of 
MUAC (the partially-shaded circle) to the hypothetical population in which women had MUAC 
at or above 23 cm (unshaded circle) (Table 4.1, scenarios 5-6). Women with MUAC 
counterfactual to these scenarios were set either below or above the cut point of 23 cm depending 
on the contrast. For example, in the scenario where all women were simulated to have normal 
MUAC, a woman with factual MUAC of 20 cm would have their simulated MUAC set to 23 cm, 
improving their nutritional status to a normal measurement of MUAC. Additionally, it is 
unrealistic to expect that an intervention could achieve complete removal of maternal 
malnutrition; therefore we also compared the observed distribution of malnutrition prevalence at 
enrollment to the population in which only 5% of each separate study population is malnourished 
at enrollment (the lowest prevalence of malnutrition from any of our studies). However, again 
this contrast requires the assumption of a hypothetical interventions with non-specific 
mechanisms to improve nutrition. Also, since we only have malnutrition assessments at 
enrollment, this assumes an intervention could be implemented that would target malnutrition 
prior to pregnancy. 
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Figure 4.1. Directed acyclic graph (DAG) created for the relationship between malaria at enrollment, malaria at 
delivery, malnutrition, and LBW. 
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Figure 4.2. Simplified directed acyclic graph (DAG) illustrating the relationship between malaria, anemia, 
malnutrition, and LBW. The dotted boxes reflect relevant variables that are unknown in the M3 dataset. The figure 
illustrates that anemia is a mediator of the relationship between malaria and LBW but is a confounder of the 
relationship between malnutrition and LBW. 
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Table 4.1. Population average causal effects, population attributable effects, and generalized intervention effects for 
the risk of low birthweight (LBW) associated with malaria infection and malnutrition during pregnancy. For 
example, the second scenario depicts the population attributable effect for malaria infection at delivery, comparing 
the risk of LBW under the observed distribution of malaria infection at delivery in the study population to the risk 
under a counterfactual setting in which there is hypothetical complete and instant eradication of malaria.  
 Exposure Contrasts Intervention 
 Malaria interventions 
1 Malaria 
infection at 
delivery 
Population average causal effect: The population with everyone exposed to 
malaria infection at delivery compared to the population of women with no 
infection. 
 
N/A 
2 Malaria 
infection at 
delivery  
Population attributable effect: 
The observed distribution of malaria infection at delivery compared to the 
population of women with no infection. 
 
Hypothetical complete 
and instant eradication 
of malaria infection at 
delivery. 
3 Bed net 
ownership at 
enrollment 
Population attributable effect:  The observed distribution of bed net 
ownership compared to the population of women where everyone owns a bed 
net. 
 
Scaling up of existing 
bed net intervention. 
4 Number of 
IPTp doses 
Generalized intervention effect:  The observed distribution of intermittent 
preventive therapy during pregnancy (IPTp) doses compared to the 
population where (i) everyone has at least two doses of IPTp, (ii) everyone 
has at least three doses of IPTp, or (iii) at least 80% of the study population 
has at least three doses of IPTp. 
 
 
 
Scaling up of existing 
IPTp interventions. 
 Malnutrition interventions 
5 Malnutrition 
at 
enrollment 
Population average causal effect: The population with everyone 
malnourished at enrollment compared to the population of women with no 
malnutrition. 
 
N/A 
6 Malnutrition 
at 
enrollment 
Population attributable effect:  The observed distribution of malnutrition 
(MUAC<23 cm) compared to the population of women with no malnutrition. 
 
Hypothetical complete 
and instant eradication 
of malnutrition prior to 
pregnancy or in early 
pregnancy. 
7 Malnutrition 
at 
enrollment 
Generalized intervention effect:  The observed distribution of malnutrition 
(MUAC<23 cm) compared to the population where only 5% of each separate 
study population is malnourished. 
 
Hypothetical 
intervention with a non-
specific mechanism that 
would reduce 
malnutrition prevalence 
in each study in M3 to 
5%. 
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CHAPTER V: COHORT PROFILE: THE MATERNAL MALARIA AND MALNUTRITION 
(M3) INITIATIVE, A POOLED BIRTH COHORT OF THIRTEEN PREGNANCY STUDIES 
IN AFRICA AND THE WESTERN PACIFIC. 1 
 
Overview 
Purpose:  
The Maternal Malaria and Malnutrition (M3) initiative has pooled together thirteen 
studies with the hope of improving understanding of malaria-nutrition interactions during 
pregnancy and to foster collaboration between nutritionists and malariologists. 
Participants:  
Data was pooled on 14,633 singleton, live birth pregnancies from women who had 
participated in one of 13 pregnancy studies. The thirteen studies cover eight countries in Africa 
and Papua New Guinea in the Western Pacific conducted from 1996 to 2015.  
Findings to date: 
Data is available at the time of antenatal enrolment of women into their respective parent 
study and  at delivery. The dataset comprises essential data such as malaria infection status, 
anthropometric assessments of maternal nutritional status, presence of anaemia, and birthweight, 
as well as additional variables such gestational age at delivery for a subset of women. 
                                                 
1 This chapter previously appeared as an article in the Journal BMJ Open. The original citation is 
as follows: Unger, Holger W., Jordan E. Cates, Julie Gutman, Valerie Briand, Nadine Fievet, 
Innocent Valea, Halidou Tinto, et al. “Maternal Malaria and Malnutrition (M3) Initiative, a 
Pooled Birth Cohort of 13 Pregnancy Studies in Africa and the Western Pacific.” BMJ Open 6, 
no. 12 (December 21, 2016). 
 
  54
Participating studies are described in detail with regards to setting and primary outcome 
measures, and summarised data is available from each contributing cohort.  
Future plans: 
This pooled birth cohort is the largest pregnancy data set to date to permit a more definite 
evaluation of the impact of plausible interactions between poor nutritional status and malaria 
infection in pregnant women on fetal growth and gestational length. Given the current 
comparative lack of large pregnancy cohorts in malaria-endemic settings, compilation of suitable 
pregnancy cohorts is likely to provide adequate statistical power to assess malaria-nutrition 
interactions, and could point towards settings where such interactions are most relevant. The M3 
cohort may thus help to identify pregnant women at high risk of  adverse outcomes who may 
benefit from tailored intensive antenatal care including nutritional supplements and alternative or 
intensified malaria prevention regimens, and the settings in which these interventions would be 
most effective. 
 
Introduction 
It is estimated that each year over 125 million pregnant women residing in low- and 
middle-income countries (LMICs) are at risk of infection with Plasmodium falciparum and P. 
vivax (4). Malaria contributes to the high burden of maternal morbidity and mortality in these 
settings and may affect placental development and fetal growth (2). Sequestration of P. 
falciparum parasites in the placenta has been associated with fetal growth restriction (FGR) and 
low birthweight (LBW, <2,500 grams), thus contributing to infant mortality and possibly long-
term health problems (119,120). P. vivax has also been associated with adverse pregnancy 
outcomes (121). Malaria during pregnancy may cause maternal anaemia, which itself can have 
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deleterious effects on fetal development (2). Maternal undernutrition is also common amongst 
pregnant women in these settings (11,122,123), and undernourished women are more likely to 
have growth-restricted fetuses and babies with reduced birthweight (17). To date it remains 
unclear whether the susceptibility to and the impact of malarial infection are affected by maternal 
nutritional status. A small number of studies suggest that macronutrient nutritional status 
modifies the effects of malaria in pregnancy, specifically the impact of P. falciparum 
parasitaemia on fetal growth and birthweight (8–10). Although largely overlooked, this may not 
be surprising given that both macro- and micronutrient nutritional status affect immune function 
more broadly (124,125). As such, there may be scope to design interventions that prevent 
adverse pregnancy outcomes by protecting women and their offspring from the deleterious 
consequences of both malaria and undernutrition. This aligns with the 2015 Global Strategy for 
Women’s, Children’s and Adolescents’ Health recommendations to reduce the risk of LBW and 
maternal anaemia through the prevention and treatment of malaria and through adequate 
nutrition during pregnancy (126,127). 
The Malaria in Pregnancy Consortium (MiPc), which receives funding from the Bill & 
Melinda Gates Foundation, brings together scientists whose aim is to reduce the burden and 
impact of malaria in pregnancy in LMICs (128,129). At the 2014 MiPc meeting in New Orleans, 
Louisiana USA, Consortium members identified the need to study the relationship between 
macronutrient nutritional status and malaria in pregnancy, given the high prevalence of 
undernutrition in malaria-endemic countries. The MiPc and other malaria researchers have 
conducted a number of malaria in pregnancy studies (observational studies and randomised 
controlled trials [RCTs] of malaria prevention strategies) and many had collected maternal 
anthropometrics and data on anaemia. Similarly, some recent trials of nutritional 
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supplementation during pregnancy collected malariometric indices. Drawing on these data, there 
is a unique opportunity to study the interaction between undernutrition and malaria, together with 
other risk factors such as maternal anaemia.  
The Maternal Malaria and Malnutrition (M3) initiative has pooled data from thirteen 
studies with the hope of improving the understanding of malaria-nutrition interactions and to 
foster collaboration between nutritionists and malariologists. Reduction of LBW and anaemia 
were two of the six global nutrition targets for 2025 agreed upon at the 2012 World Health 
Assembly (126). As of 2014, the Global Nutrition Report found that there was little progress 
towards this target (21).19 Risk factors for, and interventions to prevent, LBW are all too 
commonly studied in isolation and without cross-discipline collaboration. Topics of interest for 
M3 include an evaluation of whether macronutrient undernutrition modifies the impact of 
malaria infection during pregnancy; the investigation of potential interventions that address both 
malaria risk and nutritional status during pregnancy; and the study of the role of anaemia in 
relation to adverse pregnancy outcomes. 
Pooled cohort description 
Study populations 
The M3 initiative comprises thirteen studies (seven RCTs and six cohort studies) 
conducted amongst pregnant women in malaria-endemic countries from 1996 to 2015 
(8,37,60,70–74,76–80,88). Studies were selected based on the availability of a predetermined set 
of essential variables for each woman, adequate ethical clearance, and willingness of 
collaborators to share data. Essential variables included the assessment of malariometric indices 
(light microscopy [LM], quantitative polymerase chain reaction (qPCR), and/or rapid diagnostic 
tests [RDT]) at enrolment/first antenatal care visit (ANC), assessment of anthropometric 
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indicators at enrolment (mid-upper arm circumference [MUAC] and/or body mass index [BMI]), 
gravidity, type of malaria prevention used, and maternal age. Essential delivery outcomes 
included birthweight and newborn sex. With birthweight being the primary focus, we restricted 
inclusion to women who delivered live singleton infants without congenital abnormalities, as 
previously recommended (69).  
We included 14,633 singleton, live birth pregnancies from women who had participated 
in one of 13 pregnancy studies (Table 5.1) conducted in seven countries in Africa and one in the 
Western Pacific (Figure 5.1, Table 5.1). Of the seven RCTs, four assessed the effectiveness of 
different pharmacological malaria prevention regimens (70,71,79,80), one additionally evaluated 
nutritional supplementation (72), one was designed solely to assess the effectiveness of 
nutritional supplementation (60), and one measured the impact of insecticide-treated bed nets 
(ITNs) on birthweight (73). The six prospective cohort studies were all designed to assess risk 
factors and consequences of malaria infection and/or antimalarial treatment during pregnancy in 
different locations and among different study populations (8,74,76–78,88). 
For ten of the thirteen studies, pregnant women were identified and recruited at one of 
their self-initiated ANC, usually the booking visit but sometimes at a subsequent visit (77). The 
EMEP study enrolled women early in pregnancy, but a subset of these same women were also 
enrolled in a cross-sectional study at delivery, the IPTp-MON study (78,79). The Asembo Bay, 
ITN cohort (Kenya) identified pregnant women through monthly community census, and the 
FSP/MISAME (Burkina Faso) study recruited through a community-based network of home 
visitors (72,73). Three studies excluded HIV-infected pregnant women (37,60,80), three studies 
did not assess HIV status (70,72,74), and the remaining seven studies included both HIV-
infected and HIV-negative pregnant women.  
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The predominant malaria species observed in all studies was P. falciparum. The two 
studies in Papua New Guinea (PNG) also reported P. vivax infections (70,74). Some studies 
detected P. ovale and P. malariae infections but prevalence was very low (<1%). Studies not 
differentiating between species (n=4) were conducted in areas where P. falciparum is the 
principal malaria species, and P. vivax is thought to be largely absent (60,72,73,88).20–22,25 
Eleven studies reported high and perennial malaria transmission, while two studies reported 
medium to high perennial malaria transmission (60,70). 
Measurements 
Women in all studies had at least two study visits, at enrolment and delivery, but the 
frequency and timing of follow-up visits during pregnancy varied by study. Given logistical and 
computational intensity required in pooling longitudinal measures and substantial heterogeneity 
in frequency and timing of measurements, only data at enrolment and at delivery were pooled 
from every study. Table 5.2 and Table 5.3 show available enrolment and delivery measurements 
for each included cohort. Measurements included both those variables deemed essential for the 
main analyses on malaria, anaemia, and malnutrition, and those variables deemed optional but 
informative. A few measurements, specifically including malaria infection diagnostics, 
malnutrition anthropometrics, and anaemia diagnostics warrant further discussion. 
Malaria infection at enrolment: At enrolment malaria infection was diagnosed by 
examination of peripheral blood (82). Parasitaemia was assessed using one or more of the three 
following approaches: light microscopic (LM) examination of a Giemsa-stained blood smear, 
qPCR, and rapid diagnostic tests (RDTs) (Table 5.2). In all but two studies, malaria at enrolment 
was routinely diagnosed by LM. In the FSP/MISAME study in Burkina Faso, LM was only 
performed if a woman presented with symptoms consistent with malaria, i.e. fever or history of 
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fever (72). In the iLiNS-DYAD Ghana study, malaria was only diagnosed using a RDT (60). RDTs 
detect circulating target malaria antigens and are increasingly used in malaria-endemic areas 
when microscopy is not readily available (82,84). However, persistence of circulating target 
antigens after parasite clearance can lead to false positive test results (82). Sensitivity of qPCR is 
much higher than LM and RDTs, but the role of submicroscopic infections detected by qPCR 
alone in causing adverse outcomes has not been clearly determined (85,92). 
Malaria infection at delivery: In addition to peripheral blood diagnostics at delivery, 
some studies also assessed placental malaria infection at delivery (Table 5.3). Placental malaria 
was diagnosed by LM of a placental blood smear, qPCR, and/or placental histology (90). Three 
criteria are used to classify placental malaria by histology: presence of infected erythrocytes; 
haemozoin in monocytes/macrophages; and haemozoin in fibrin deposits (91). Placental 
histology is considered the diagnostic reference standard for placental infection.  
Mid-upper arm circumference (MUAC) and body mass index (BMI): Maternal 
macronutrient nutritional status was assessed by measurement of women’s MUAC and/or BMI at 
enrolment. MUAC, the circumference of the upper arm, assessed at the mid-point between the 
elbow and the tip of the shoulder, is frequently used as a broad indicator of maternal protein 
reserves, fat stores, and macronutrient nutritional status (94). MUAC was measured in ten of the 
thirteen studies, which included 61% of our total study population (Table 5.2). Weight and 
height (to derive BMI) were additionally measured in nine of these studies as well as in the three 
studies where MUAC was unavailable (Table 5.2). While neither measurement is perfect, 
MUAC and BMI are easy and low-cost nutritional assessments that can be undertaken in low-
resource settings, and are clinically relevant (93). 
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Anaemia at enrolment: Most women had haemoglobin measurements done at first ANC, 
and most received routine iron/folate supplements, although information on their use was not 
routinely collected. The dosage of folate supplementation (0.4 to 5 mg) varied by study site.  
Findings to date 
Findings from each individual study emphasise how pooling this data has the potential to 
generate important information on malaria-nutrition interactions in pregnancy.  
The ECHO study in the DRC was the first study to report an interaction between malaria and 
malnutrition on the risk of FGR (8). In this study, the risk of FGR was two to eight times higher 
among women with evidence of malnutrition. In this study, the magnitude of the difference in 
effect sizes depended on the measurement for malnutrition (BMI vs MUAC vs short stature vs 
weight gain) and the measurement for malaria (cross-sectional versus cumulative); however, 
with all measurements of malnutrition and malaria the pattern and directionality of the 
modification was consistent. This study, together with a small number of follow-up studies, 
provided the necessary preliminary data for the M3 initiative (9,11). 
Two participating studies provided evidence regarding nutritional interventions during 
pregnancy. The FSP/MISAME in Burkina Faso study concluded that multiple micronutrient-
fortified food supplementation (FFS) increased mean birthweight, and that this effect was most 
pronounced amongst women who were anaemic or undernourished early in their pregnancy 
(130). The iLiNS-DYAD trial in Ghana found modest overall increases in birthweight with the 
provision of lipid-based nutrient supplements compared to iron and folic acid supplementation, 
but showed that the intervention may be most effective when given to primiparous women (60). 
While nutritional assessment was not the primary aim of the remaining studies, the IPTp RCT in 
PNG and the STOPPAM cohort study in Benin reported associations between low maternal 
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anthropometrics and birthweight (88,131). 
Other studies largely focused on malaria prevention. In the late 90s, the Kisumu cohort 
study found that implementation of two doses of IPT-SP halved the prevalence of placental 
malaria infection. In another study conducted concurrently in Kenya (Asembo Bay study) use of 
ITNs was associated with a marked reduction in placental malaria and LBW, but (as expected) 
with no apparent impact on nutritional status (73). The LAIS study, conducted in Malawi from 
2003-2006, found that adding azithromycin to two courses of monthly SP (SPAZ) was better at 
reducing malaria at delivery, LBW, and preterm birth than monthly SP or two doses of SP 
(71,132,133). SPAZ was also superior when compared to the standard malaria prevention 
regimen used in PNG (SP plus chloroquine),(70) where placental infection is an important risk 
factor for LBW (74). The EMEP cohort study found that use of artemisinin combination 
treatments during the first trimester was not associated with increased risk of miscarriage (78). 
The IPTp-MON study found that with increasing resistance, the efficacy of IPTp-SP in clearing 
existing infections or preventing new ones is compromised, however, where the sextuple mutant 
is rare, it remains associated with improvements in birthweight and maternal haemoglobin (79). 
The STOPPAM cohort studies conducted in Benin and Tanzania provided observational 
data on the effects and potential limitations of two-dose IPTp-SP. Specifically, the STOPPAM-
Benin study found that a substantial proportion of women acquired malaria infections late in 
pregnancy, some time after the second IPTp dose had been given (88). The STOPPAM-Tanzania 
study also found that malaria infections in the first or second trimester were associated with 
altered fetal growth that might not be detectable until the 3rd trimester (76). Trial data from the 
FSP/MISAME study further corroborated these observational studies; the FSP/MISAME study 
found that malaria infection during the first trimester was associated with higher risk of LBW 
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and that additional doses of IPTp might be more effective (72,134). These studies, along with 
others, have highlighted the importance of early and frequent malaria prevention to improve birth 
outcomes, and IPT-SP is now routinely given monthly until delivery (34,135). 
The ISTp Malawi study assessed another malaria prevention strategy by comparing IPTp-
SP to IPTp with intermittent screening for malaria infection (ISTp) at ANC visits using RDTs 
and treating infected women with dihydroartemisinin-piperaquine (DHA-PQ) (38). The 
STOPMIP Kenya study also assessed ISTp with DHA-PQ, comparing it to IPTp with DHA-PQ 
as well as IPTp-SP. Analyses from both studies suggest that ISTp-DHA-PQ is not superior to the 
existing strategy of IPTp-SP, although IPTp-DHA-PQ was more effective than both ISTp-DP 
and IPTp-SP (37).  
Future plans 
We plan to assess whether maternal macronutrient nutritional status, as assessed by 
MUAC, BMI and maternal height, alters the risk of reduced birthweight that is associated with 
malaria infection during pregnancy. Among women who underwent a dating ultrasound in early 
pregnancy, analyses will be performed using preterm birth and small-for-gestational age as 
endpoints instead of LBW. To inform policy decisions, we further plan to use advanced 
epidemiologic methods to stochastically model the impact that plausible targeted antimalarial 
and nutritional interventions during pregnancy could have on the number of babies born LBW in 
malaria endemic areas (13–15). Additional future analyses include, but are not limited to, the 
following: the impact of anaemia on LBW; the interaction between anaemia and malaria with 
regards to increasing the risk of LBW; the mediation of the effect of malaria through anaemia on 
LBW; and the usefulness and agreement of MUAC versus BMI to predict adverse birth 
outcomes. Short maternal stature, potentially indicative of stunting and reduced adolescent catch-
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up growth (chronic undernutrition), has also been associated with increased risks of adverse birth 
outcomes and will be explored using this pooled dataset (136). Finally, we will assess 
aforementioned relationships and effects amongst pregnant women with HIV, a patient cohort 
known to be at increased risk of adverse outcomes due to malaria and malnutrition (63). 
Strengths and limitations 
This pooled birth cohort holds promise as the largest pregnancy dataset to date to address 
questions regarding malaria and nutrition that are of great importance to maternal and infant 
health. Prior research on this topic has been limited by insufficient statistical power to examine 
the interaction between malaria and malnutrition. The pooled M3 provides offers the opportunity 
to overcome this limitation by increasing statistical power and precision, which is particularly 
valuable for conducting subgroup analyses and investigating interactions. The substantial size of 
the pooled dataset also facilitates the application of rigorous methodological approaches for 
systematically missing data, such as multiple imputation by chained equations, standardisation, 
latent variable methods, or transformation of measurements to create commensurate measures 
(137,138). Availability of individual-level data, rather than aggregate data from each study, 
allows definitions of exposures and outcomes to be harmonised.  Individual-level information on 
malaria and malnutrition further enables implementation of complex modelling to assess targeted 
antimalarial and nutritional interventions during pregnancy. The diversity of study populations 
included in the M3 cohort, e.g. with respect to location, ethnicity, malaria transmission intensity, 
malaria and nutrition interventions, health infrastructure, and HIV prevalence, could provide 
important data with regards to generalisability of our findings. Specifically, this level of 
population diversity, coupled with availability of data on multiple risk factors for LBW and 
greater statistical power to assess subgroup effects, may allow the identification of high risk 
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women who could benefit most from more intensive antenatal care, nutritional supplements, and 
alternative malaria prevention regimens, and of the settings in which these interventions would 
be most effective.  
The main limitations of the pooled dataset are related to missing data and heterogeneity 
of collected data. First, information that was collected by all studies varied, leading to 
systematically missing data on a number of important variables (Tables 5.2 and 5.3). The limited 
availability of accurately measured gestational age hinders the ability to conduct preterm birth 
and small-for-gestational age analyses for the entire dataset (Table 5.3), but should allow for 
meaningful subanalyses. Second, exclusion of miscarriages and stillbirths may cause selection 
bias (left truncation) for some analyses, given the possibility of differential rates of early 
pregnancy losses in relation to infection and nutritional status (139). We will assess this potential 
bias using data on miscarriages and stillbirths extracted from a subset of studies (37,38,72,78). 
Third, potential confounders such as concomitant helminth infection and micronutrient 
deficiencies were not measured in participant studies (140,141). Fourth, while MUAC only 
modestly changes throughout pregnancy, BMI tends to increase with gestational age: gestational 
age-adjusted BMI may be one approach to address this problem. Fifth, while we have 
information on HIV status for a majority of studies, information on use of antiretroviral therapy 
(ART) was not extracted, and secular changes over time regarding use and efficacy of ARTs 
could influence the comparability of results across studies that enrolled HIV-infected women. 
Finally, since the intention was to concentrate on areas of moderate to high P. falciparum 
transmission, we did not include any studies representing other malaria-affected regions such as 
Central/South America and India.   
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Table 5.1. Characteristics of the 13 individual studies included in the Maternal Malnutrition and Malaria (M3) 
Initiative.  
Countries Study Name Design Period Median 
GA 
(IQR)* 
Malaria 
prevention† 
Nutritional 
intervention 
N‡ n§ 
Benin STOPPAM I Cohort 2008-
2010 
 
17 (14-20) IPT-SP  None 1037 791 
BF FSP/MISAME RCT 2006-
2008 
16 (11-21) IPT-SP(2), 
IPT-SP(3)  
MMS, FFS 1296 1020 
DRC ECHO Cohort 2005-
2006 
 
19 (17-21) IPT-SP None 182 164 
Ghana iLiNS-DYAD RCT 2009-
2012 
 
17 (15-20) IPT-SP LNS, MMN, 
IFA  
1320 1068 
Kenya EMEP & 
IPTpMon 
Cohort # 2011-
2013 
23 (16-30) IPTp-SP None 1453 471# 
Kenya ITN RCT 1996-
1999 
24 (20-30) IPT-SP 
started during 
study  
None 911 711 
Kenya Kisumu cohort Cohort 1996-
2001 
36 (34-37) IPT-SP 
started during 
study 
None 3155 3388** 
Kenya STOPMIP RCT 2012-
2015 
23 (20-26) IPT-SP, IPT-
DHA-PQ, 
IST-DHA-PQ 
None 1546 1203 
Malawi ISTp RCT 2011-
2013 
 
21 (19-23) IPT-SP, IST-
DP 
None 1873 1602 
Malawi LAIS RCT 2003-
2006 
 
20 (18-23) IPT-SP(2), 
IPT-SP(4) 
IPT-SPAZ 
None 1320 1190 
PNG IPTp study RCT 2009-
2013 
 
22 (19-25) IPT-SPAZ; 
Single dose 
SP and 
weekly CQ  
None 2793 1943 
PNG Sek cohort Cohort 2005-
2007 
 
25 (22-28) Single dose 
SP and 
weekly CQ  
None 470 293 
Tanzania STOPPAM II Cohort 2008-
2010 
 
19 (15-21) IPT-SP  None 995 789 
BF=Burkina Faso. CQ= chloroquine. DHA-PQ=Dihydroartemisinin-piperaquine. DRC=Democratic Republic of the Congo. FFS=fortified food 
supplementation. IFA=iron and folic acid supplementation. IPT (doses)=intermittent preventive treatment in pregnancy. IST=intermittent 
screening for malaria infection. LNS=lipid-based nutrient supplementation. MMS=multiple micronutrients supplementation. PNG=Papua New 
Guinea. RCT=randomised controlled trial. SP=sulphadoxine-pyrimethamine. SPAZ= SP and azithromycin.  
* Median (IQR): Gestational age at enrolment assessed by fetal biometry, or symphysis-pubis fundal height when ultrasound unavailable. 
†If RCT, describes the intervention, if cohort, describes the national policy during the study period  
‡N=Enrolled in parent study. 
§ n=live birth pregnancies that met inclusion criteria for M3.  
# The EMEP study was a prospective cohort study with some overlapping enrolment with the cross-sectional study IPTp-MON. 111 pregnancies 
were enrolled in both EMEP and IPTp- MON; information on malaria infection at delivery was obtained for the subset of women in IPTp-MON. 
**Includes additional women from a sub-study not included in the parent study which otherwise met inclusion criteria for the pooled data. 
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Table 5.2. Key measures at enrolment across the 13 studies included in the Maternal Malnutrition and Malaria (M3) Initiative.  
Variable STOPPAM
- Benin 
FSP/ 
MISAME
- BF 
ECHO
- DRC 
iLiNS-
DYAD-
Ghana 
EMEP& 
IPTpMon-
Kenya 
ITN- 
Kenya 
Kisumu
- Kenya 
STOPMIP
-Kenya 
ISTp-
Malawi 
LAIS-
Malawi 
IPTp-
PNG 
Sek-
PNG 
STOPPAM
-Tanzania 
Essential              
Malaria              
LM X X* X  X X X X X X X X X 
PCR        X X  X X  
RDT X†   X‡    X§ X§    X† 
Anthropometrics              
MUAC X* X X X  X*  X#  X X X X 
Weight X X X X X X X X X X X X X 
Height X X X X X X X X X X X  X 
Gravidity X X X X X X X X X X X X X 
Anaemia††              
Haemoglobin X X  X X X X X X X X X X 
Haematocrit   X           
Optional              
Gestational age              
Ultrasound X X X X X*    X X X*  X 
Fundal height X X* X X X* X X X X X X X X 
Age X X X X X X X X X X X X X 
Smoking (Y/N) X  X  X     X X X X 
HIV X  X X X X* X X X X   X 
Rural/urban area X  X X X X X X X X X X X 
Bed net X  X   X  X X X X X X* 
Available information indicated with X, missing data >10% indicated by asterisk, and systematically missing data indicated with grey highlighting. 
BF=Burkina Faso. DRC=Democratic Republic of the Congo. HIV=human immunodeficiency virus. IPTp=intermittent preventive treatment in pregnancy. ISTp=intermittent 
screening for malaria infection in pregnancy. ITN=insecticide-treated bed nets. LM=light microscopy. MUAC=mid-upper arm circumference. PNG=Papua New Guinea. 
PRC=polymerase chain reaction. RDT=rapid diagnostic test.  
† The STOPPAM Benin and Tanzania studies primarily used the Parascreen RDT (Zephyr Biomedical Systems, Goa, India), which detects P. falciparum histidine protein-2 (HRP-
2) and Plasmodium lactate dehydrogenase (pLDH).  
‡ The iLiNS-DYAD-Ghana study used the Clearview Malaria Combo RDT (British Biocell International Ltd., Dundee, United Kingdom), which detects HRP-2 and plasmodium  
aldolase.  
§ Women randomized to the ISTp arms of the STOPMIP-Kenya and ISTp-Malawi studies were tested with a First Response Malaria Ag. (pLDH/HRP2) Combo RDT (Premier 
Medical Corporation, India).  
# Maternal MUAC measured at delivery. 
†† Nine studies measured haemoglobin using a HemoCue haemoglobinometer (Hemocue, Angelholm, Sweden),20–22,26–31 one study relied on haemoglobin measures from a local 
laboratory (unknown make),23 one study used Sysmex hematological analyzer (Kobe, Japan),32 and one study collected capillary blood (finger stick) specimens for determination 
of haematocrit or haemoglobin levels using a standardised chart.10 In the ITN-Kenya study, haemoglobin was measured using a HemoCue haemoglobinometer (Hemocue, 
Angelholm, Sweden) before 1997, and from 1997 onwards capillary blood (finger stick) specimens were collected for determination of haematocrit levels, which were divided by a 
factor of three and presented as haemoglobin values for consistency with the 1996 data.  
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Table 5.3. Key measures at delivery across the 13 studies included in the Maternal Malnutrition and Malaria (M3) Initiative.  
Variable STOPPAM
- Benin 
FSP/ 
MISAME
- BF 
ECHO
- DRC 
iLiNS-
DYAD-
Ghana 
EMEP& 
IPTpMon-
Kenya 
ITN- 
Kenya 
Kisumu
- Kenya 
STOPMIP
-Kenya 
ISTp-
Malawi 
LAIS-
Malawi 
IPTp-
PNG 
Sek-
PNG 
STOPPAM
-Tanzania 
Essential variables              
Malaria- peripheral              
LM X* X* X  X*† X X X X X* X X X 
PCR          X* X X  
Malaria-placental              
LM X* X*   X*† X X X X  X* X* X* 
PCR        X X  X* X* X* 
Histology   X     X X  X* X*  
IPTp doses X X* X  X   X X* X X  X 
Birthweight X X X X X X X X X X X X X 
Infant sex X X X X X X X X X X X X X 
Optional variables              
Gestational age              
By ultrasound X X X X X*    X X X*  X 
Neonatal 
anthropometrics 
             
Abdomen 
circumference 
X*  X        X  X 
Chest 
circumference 
 X        X    
Head 
circumference 
X X X X X   X X X X X X 
Crown heel length  X X X X X  X   X X  
Timing of 
anthropometrics 
X  X X X X X X X X X X X 
Available information indicated with X, missing data >10% indicated by asterisk, and systematically missing data indicated with grey highlighting. 
BF=Burkina Faso. DRC=Democratic Republic of the Congo. IPTp=intermittent preventive treatment in pregnancy. ISTp=intermittent screening for malaria infection in pregnancy. 
ITN=insecticide-treated bed nets. LM=light microscopy. PNG=Papua New Guinea. PRC=polymerase chain reaction  
† For the EMEP/IPTpMON study, only women co-enrolled in the IPTpMON study (n=111) had malaria diagnostics at delivery. 
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CHAPTER VI: MALARIA, MALNUTRITION, AND BIRTH WEIGHT:  
A POOLED ANALYSIS OF 14,633 PREGNANCIES  
 
Introduction 
Annually, over 20 million infants are born low birthweight (LBW; <2500 g), 
predominantly in low- and middle-income countries (LMICs) (16). LBW can have negative 
impacts on neonatal mortality and childhood neurological, metabolic, and physical development 
(2). The World Health Organization (WHO) has set a Global Nutrition Target of 30% reduction 
in LBW by 2025 (16). 
One preventable cause of LBW in LMICs is maternal malaria infection (1,2). Its 
prevalence remains high, despite targeted malaria prevention programs (2). Annually, 125 
million pregnant women are at risk for malaria (4). The predominant species, Plasmodium 
falciparum, sequesters in the placenta, causing LBW through fetal growth restriction (FGR) and 
preterm delivery (2). Prior estimates from Africa suggest that malaria infection doubles the risk 
of LBW (2,4). Prevention of malaria in pregnancy remains a public health priority.  
Another modifiable risk factor for impaired fetal growth is maternal malnutrition, 
specifically undernutrition (17). Up to 20% of African women of reproductive age are 
undernourished (17,46,93). Maternal protein-energy-fat (macronutrient) and micronutrient 
reserves and dietary consumption influence fetal growth. Micronutrient deficiencies are difficult 
and costly to assess and therefore anthropometrics are commonly used as sensitive but non-
specific indicators of protein reserves, fat stores, and malnutrition more broadly (93).  
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Recent evidence indicates that the relationship between malaria infection and LBW may 
depend upon the mother’s nutritional status (51). Studies in Papua New Guinea (PNG) and Benin 
found inconsistent evidence of modification of the malaria infection -LBW relationship by 
maternal anthropometric status, but studies from Kenya and the Democratic Republic of the 
Congo (DRC) reported significant modification (8,9,11,12). Notably, in DRC the risk of FGR 
associated with malaria infection was two to eight times higher among malnourished women (8). 
Malaria infection and malnutrition may act along similar physiological pathways by affecting 
placental development and nutrient transfer (2,4,17). 
To date, work on this potential interaction has been limited to 4 studies with only 1,318 
pregnant women from Africa and 1,369 pregnant women from PNG. Not only were these studies 
somewhat inconsistent in their findings, but their interpretation is hindered by relatively small 
sample sizes, potentially limiting their generalizability to other malaria -endemic countries. The 
objective of this study was to investigate the putative interaction between maternal malaria 
infection and malnutrition in relation to LBW using a large pooled dataset of thirteen studies 
conducted in multiple LMICs. We hypothesized that there would be a synergistic interaction, 
such that the observed joint effect of being both infected with malaria and malnourished would 
be greater than expected if considering each exposure independently.  
 
Methods 
Study population 
We used data from 14,633 singleton live birth pregnancies from women participating in 
thirteen studies in eight African countries and the Western Pacific (PNG) as part of the Maternal 
Malaria and Malnutrition (M3) initiative (8,11,37,60,71–75,77–80,142).  
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Outcomes and exposures 
The main outcome was birth weight (BW), analyzed continuously and dichotomized at 
2,500 grams (LBW) (16). Weights measured after 24 hours (13% of weights) were adjusted 
using a cubic regression model to account for weight changes in the first week of life (143). 
Among nine studies with ultrasound-dated gestational age we used small-for-gestational age 
(SGA) as a secondary outcome, defined as a BW less than the 10th percentile of the 
INTERGROWTH-21st reference (25).  
Diagnostics for malaria were collected at study enrollment and at delivery. At study 
enrollment, we defined malaria based on light microscopic (LM) examination of a Giemsa-
stained peripheral blood smear or a rapid diagnostic test (RDT) for malaria antigen (28). At 
delivery, we defined malaria based on peripheral or placental LM or placental histology (active 
or past infection). Given the uncertain impact of sub-microscopic infections on LBW and the 
variation in availability of polymerase chain reaction (PCR) diagnostics across studies, we 
excluded PCR results (92). In sensitivity analyses, we explored definitions of malaria including 
PCR results, and ‘any malaria’, defined as a positive LM, RDT, or PCR at enrollment, delivery, 
or during pregnancy (in five studies with relevant data).  
The primary measure of maternal malnutrition was low mid-upper arm circumference 
(MUAC) at enrollment, dichotomized at 23 cm (93). MUAC changes little over pregnancy, 
making it a useful measure of malnutrition (93). Since some studies did not measure MUAC, we 
used body mass index (BMI) as a secondary measure of malnutrition. According to the WHO, a 
pre-pregnancy BMI <18.5 kg/m2 is predictive of adverse birth outcomes (48). BMI at enrollment 
was used to estimate pre-pregnancy BMI by adjusting maternal weight measured in the 
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second/third trimesters using a cubic regression model to account for gestational weight gain 
(48). Low adjusted-BMI was defined as values under 18.5 kg/m2. As the correlation between 
BMI and MUAC is not perfect, indicators were analyzed separately (93). 
 
Statistical analysis 
We analyzed maternal malaria infection and malnutrition as co-primary exposures and 
assessed malnutrition as a modifier of the malaria -LBW relationship. While effect measure 
modification (EMM) assesses how the effect of one exposure varies across strata of another 
variable, interaction analyses assess the joint effects of two exposures (114). We performed both 
interaction and EMM analyses, however in the context of this work, interaction is preferable to 
EMM because interventions for both malaria infection and malnutrition might prevent LBW. 
We employed a two-stage approach for pooling individual-level data from each study. 
We examined the consistency of results with a one-stage approach, fitting a generalized mixed 
model with random intercepts and slopes. Study-specific risk ratios (RRs) and mean BW 
differences were calculated using linear and log binomial regression models controlling for 
confounding using inverse probability of treatment weights (IPTW) truncated at the 1st and 99th 
percentiles. A minimally sufficient set of confounders was identified using a directed acyclic 
graph based upon background knowledge of covariate relationships (116). We identified 
confounders for both malaria infection and malnutrition relative to LBW since we were 
analyzing them as co-primary exposures. Confounders for the relationship between malaria 
infection at enrollment and LBW included maternal age, gravidity, rural versus urban residence, 
malnutrition (MUAC when available, otherwise BMI), and HIV infection. Because malaria 
infection is a cause of anemia, the latter was considered a mediator, and not a confounder. We 
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explored modification of the effect of malaria infection at enrollment on LBW by maternal 
gravidity and doses of intermittent preventive therapy (IPTp) received. When assessing malaria 
infection at delivery, anemia at enrollment and the number of IPTp doses were considered 
confounders. Confounders for the malnutrition-LBW relationship included maternal age, 
gravidity, rural versus urban residence, anemia at enrollment, and HIV infection. Partially 
missing data were imputed using multivariate normal multiple imputation (144). We calculated 
interaction estimates using a product term in the multiplicative and additive model for LBW and 
the additive model for mean BW (114). These estimates reflect whether the effect of exposure to 
both malaria infection and malnutrition exceeds the product (or sum) of the effects of each 
exposure considered separately, and quantifies this difference. A product term greater than one 
on the multiplicative scale or greater than zero on the additive scale is indicative of interaction 
between malaria infection and malnutrition. 
Study-specific estimates were pooled using DerSimonian and Laird restricted maximum 
likelihood method random effects models (109). When , the estimated variance of the random 
effects distribution, was greater than zero, we calculated 95% population effects intervals (PEI), 
which incorporate the estimated variance between studies (109). If equaled zero, the random 
effects model was interpreted as a fixed effects model.  We decided a priori to evaluate 
modification of the results by time period (before versus after 2008) due to changes in 
antimalarial recommendations, study type (trial/cohort), location (Africa/Western Pacific), and 
malaria infection prevalence (based on M3 data), using meta-regression. 
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Results 
Study population characteristics 
The trimester at enrollment, anemia prevalence, gravidity distribution, area of residence, 
and HIV prevalence varied across studies (Table 6.1). The prevalence of malaria infection at 
enrollment, low MUAC, and joint malaria infection and low MUAC also varied by study (Figure 
6.1).  Among 8,152 women with both measurements, only 2% had both low MUAC and malaria 
infection at enrollment. The prevalence of malaria infection among women with low MUAC was 
16%, compared to 12% among well-nourished women (p=0.0005). The prevalence of low BMI 
varied across studies, and was different from, although correlated with, the prevalence of low 
MUAC ( p<.0001; Supplemental Figure 6.1). The joint prevalence of malaria infection at 
enrollment and low BMI was also 2%. Of all 14,633 women, 35% were infected with malaria at 
either enrollment or delivery or had low MUAC or BMI. The prevalence of LBW was 9% (range 
5% to 15%). 
 
Independent effects of malaria infection and malnutrition  
The pooled IPTW-adjusted risk ratio (aRR) for the effect of malaria infection at 
enrollment on LBW was 1.14 (95% CI: 0.91, 1.42; 95% PEI: 0.72, 1.80), and the mean BW 
difference was -55 g (95% CI: -79, -30) (Figure 6.2a). The effect of malaria infection at delivery 
was more pronounced: aRR, 1.32 (95% CI: 1.08, 1.62; 95% PEI: 0.91, 1.91) (Figure 6.2b). When 
considering SGA as the outcome, results were the same for malaria infection at enrollment and 
slightly attenuated for malaria infection at delivery. The effect of malaria infection at enrollment 
was attenuated among those with more than one IPTp dose versus one or zero doses (aRR 0.98 
vs 1.22) and was stronger among primi/secundigravid versus multigravida women (aRR 1.19 vs 
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1.14). A slightly stronger effect of malaria infection was seen among women enrolled in studies 
conducted prior to 2008, in Africa, or with malaria infection prevalence at or above the median 
(Supplemental Figure 6.2).  
The aRR for the effect of low MUAC on LBW was 1.60 (95% CI: 1.34, 1.87); the mean 
BW difference was -142g (95% CI: -171, -113) (Figure 6.3a). Results were similar for low BMI: 
aRR, 1.49 (95% CI: 1.26, 1.76); mean BW difference -133g (95% CI: -158, -108) (Figure 6.3b). 
There was no modification by study characteristics on the malnutrition-LBW relationship 
(Supplemental Figure 6.3). Similar trends were observed when SGA was used as the outcome 
among the studies with ultrasound data. 
 
Interaction and EMM  
 The joint aRR for both malaria infection at enrollment and low MUAC was 2.13 (95% 
CI: 1.21, 3.73; 95% PEI: 0.80, 5.67) and the mean BW difference was -163 g (95% CI: -253, -
75; 95% PEI: -328, 0). The multiplicative interaction term for LBW was 1.30 (95% CI: 0.62, 
2.72; 95% PEI: 0.39, 4.31), the additive interaction term for LBW was -0.01 (95% CI: -0.09, 
0.08; 95% PEI: -0.13, 0.11), and the additive interaction term for mean BW difference was 38 g 
(95% CI: -90, 166; 95% PEI: -219, 295). Sensitivity analyses that varied the definitions of 
malaria, malnutrition, outcome, and analytic approach did not qualitatively alter the results 
(Supplemental Table 6.1). Meta-regression indicated apparent multiplicative interaction and 
slight additive interaction between MUAC and malaria infection at enrollment among studies 
conducted in Africa (multiplicative interaction term, 2.47 (95% CI: 1.12, 5.42); additive 
interaction contrast, 0.06 (95% CI: -0.05, 0.17) Supplemental 6.4), but this interaction was not 
seen when assessing malaria infection at delivery or BMI or when accounting for multiple 
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comparisons with a Bonferroni correction (99% CI: 0.88, 6.95). In EMM analyses, the aRR for 
the effect of malaria infection at enrollment on LBW among low MUAC women was 1.32 (95% 
CI: 0.66, 2.63; 95% PEI: 0.36, 4.79), compared to 0.98 (95% CI: 0.74, 1.29) among well-
nourished women.  
 
Discussion 
Using the large M3 dataset, we found that pregnant women who were both infected with 
malaria and malnourished were at greater risk of LBW and reduced mean BW compared to their 
uninfected, well-nourished counterparts. The relative risk of LBW associated with joint malaria 
infection at enrollment and low MUAC was 2.13 (95% CI: 1.21, 3.73; 95% PEI: 0.80, 5.67). 
While this relative risk was greater than the individual effects of malaria infection and 
malnutrition separately, there was overall no convincing evidence of synergism, i.e. excess risk 
due to interaction. This suggests that malaria infection and malnutrition largely act independently 
to influence fetal growth.  
A 2004 review estimated that women infected with placental malaria were twice as likely 
to have a LBW infant (19). Our findings are broadly consistent with this review, although with 
weaker effects on LBW (overall aRR for malaria infection at delivery: 1.32 [95% CI: 1.08, 1.62], 
aRR restricted to African studies: 1.55 [95% CI: 1.29, 1.85]), possibly reflecting increased access 
to preventive strategies and fewer chronic infections (1,4). In support of this, the effect of 
malaria infection on LBW appears lower in women who received more doses of IPTp. The 
effects of malaria infection at enrollment on LBW were weaker than at delivery, contradicting 
the theory that malaria infection earlier in pregnancy is more disruptive to placental function (2). 
This weaker effect at enrollment could either suggest that antimalarial treatment, provided in 
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most studies, cleared infection and allowed catch-up growth or that infection at delivery 
represents more severe infections that were not cleared despite medications.  
Our data are consistent with a 2011 meta-analysis, which estimated that underweight 
women had increased risks of LBW (aRR: 1.64 [95% CI: 1.38, 1.94]), although studies included 
in that meta-analysis used different definitions for underweight (52). In our study, using 
consistent cut points of malnutrition across studies, both low MUAC (aRR 1.60 [95% CI: 1.36, 
1.87]) and low BMI (aRR 1.49 [95% CI: 1.26, 1.76]) increased the risk of LBW. This 
information is consistent with other evidence that adequate maternal nutrition is integral for fetal 
growth (17). 
Prior literature on the interaction between malaria infection and malnutrition is sparse. 
Two studies in the DRC and Kenya showed that the association between malaria infection and 
reduced fetal growth was greatest among malnourished women (8,9). In a third study in Benin, 
the effect of malaria infection on fetal growth velocity was greatest among women with low 
anthropometric status, but there was no modification of the effect of malaria infection on 
birthweight z-scores. A fourth study in PNG found that the effect of histology-defined placental 
malaria infection on LBW was higher among women with a low BMI, but found malnutrition did 
not modify the association between peripheral blood malaria infection parasitemia and SGA (11). 
The Benin, Congo, and PNG studies were included in the present analysis, but our analytic 
approach differed from the original publications in the assessment of both interaction and 
modification. Unlike these prior studies, our pooled results suggest that there is a negligible 
impact of maternal anthropometry on the relationship between malaria infection and LBW and 
further indicate that there is no evidence of excess risk of LBW due to interaction (i.e. 
synergism). We note that in an a priori sensitivity analysis restricted to African studies, there 
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was apparent interaction between malaria infection at enrollment and MUAC, which is 
consistent with the prior publications. Regional differences could be due to genetics, low MUAC 
or anemia prevalence; however, these sub-region effects were not statistically significant when 
properly accounting for multiple comparisons, and were absent when using other definitions of 
malaria (i.e. at delivery) or malnutrition (i.e. BMI). Notably, only 183 women (2%) were jointly 
infected and malnourished (low MUAC). Thus, even if there is a multiplicative interaction 
between malaria infection and MUAC among African women, the proportion of women 
implicated is small, and does not indicate a large public health burden. However, even in the 
absence of strong interaction between malaria infection and malnutrition on LBW, we emphasize 
that interventions on both malaria infection and malnutrition are warranted given their 
independent effects.  
This work had several strengths and limitations. We substantially increased the number 
of women in whom the hypothesized interaction between malaria infection, malnutrition, and 
LBW was investigated; notably, the number of pregnant women from Africa was almost ten 
times more than all prior studies. Analyzed studies were performed in a variety of settings, 
increasing the generalizability of these results. Furthermore, availability of individual-level data 
enabled us to harmonize definitions and minimize heterogeneity. On the other hand, we were 
obliged to pool malaria diagnostics of varying sensitivity and specificity, and we were limited to 
two cross-sectional assessments of malaria infection. Nevertheless, sensitivity analyses that 
evaluated alternative definitions of malaria, or incorporated repeat diagnostics during pregnancy, 
were consistent with the main results. Additionally, there may be selection bias due to excluding 
pregnancy losses. There were only 116 (3%) pregnancy losses in four studies (N=4,571) in M3 
that collected these data, but this is almost certainly an underestimate, since many studies 
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enrolled women after the first trimester. We were limited to extrapolating a pre-pregnancy BMI 
using gestational age and BMI at enrollment. Additionally, the M3 was a convenience sample of 
studies with available malaria and nutrition measurements, rather than a random sample of extant 
data. Furthermore, women enrolled in studies were likely healthier and received better antenatal 
care than the general population; the effects of malaria and malnutrition in reality might well be 
greater than observed within these research settings. Finally, we cannot discount possible 
unmeasured confounding, particularly by helminth infections, sexually transmitted infections, 
environmental pollutants, or micronutrient deficiencies; however, it is important to note that 
because neither malnutrition nor malaria could be randomized, large-scale, multi-site cohort 
analyses such as this one are necessarily the gold standard for addressing these scientific 
questions. Future studies may wish to explore joint effects of malaria and other nutritional 
indicators (e.g., height, obesity, anemia) on preterm birth as well as SGA and LBW. 
In summary, our findings suggest that women who are both infected with malaria and 
malnourished are at greater risk of LBW than their uninfected, well-nourished counterparts, but 
that there is no conclusive evidence of synergistic interaction between the two. Rather, we 
propose that malaria infection and malnutrition act independently to disrupt fetal growth, and 
that malnutrition in particular has a strong effect on LBW. Of all 14,633 pregnancies, 35% were 
affected by malaria infection and/or malnutrition, illustrating the high burden of at-risk 
pregnancies in LMICs. Malaria infection and malnutrition represent two established and 
modifiable causes of LBW that should both be addressed to optimize pregnancy outcomes in 
LMIC. 
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Table 6.1. Characteristics of women participating in thirteen studies included in the Maternal Malaria and Malnutrition (M3) initiative 
 Kisumu- Kenya 
 
(N=3388) 
IPTp-PNG 
 
(N=1943) 
ISTp-Malawi 
 
(N=1602) 
STOPMIP-Kenya  
 
(N=1203) 
LAIS-Malawi 
 
(N=1190) 
iLiNS-Ghana 
 
(N=1068) 
Study enrollment (years) 1996-2001 2009-2013 2011-2013 2012-2015 2003-2006 2009-2012 
Maternal age 20 (18-24) 24 (20-28) 21 (18-26) 22 (19-27) 24 (20-29) 26 (22-30) 
Gravidity       
1 (Primi-) 1656 (49) 966 (50) 542 (34) 403 (34) 267 (22) 349 (33) 
2 (Secundi-) 748 (22) 494 (21) 448 (28) 237 (20) 213 (18) 351 (33) 
3+ (Multi-) 984 (29) 573 (29) 612 (38) 563 (47) 710 (60) 368 (34) 
Trimester*       
1 0 (0) 72 (4) 0 (0) 21 (2) 0 (0) 103 (10) 
2 0 (0) 1780 (92) 1585 (99) 991 (82) 1190 (100) 881 (82) 
3 3388 (100) 91 (5) 17 (1) 191 (16) 0 (0) 81 (8) 
Missing GA 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (0) 
Anemic†       
Yes 2548 (75) 1348 (69) 533 (33) 591 (49) 459 (39) 305 (29) 
No 808 (24) 512 (26) 1069 (67) 612 (51) 731 (61) 763 (71) 
Missing 32 (1) 83 (4) 0 (0) 0 (0) 0 (0) 0 (0) 
HIV       
Yes 810 (24) - 0 (0) 0 (0) 144 (12) 0 (0) 
No 2560 (76) - 1602 (100) 1203 (100) 931 (78) 1059 (99) 
Missing 18 (1) 1943 (100) 0 (0) 0 (0) 115 (10) 9 (1) 
Area of Residence       
Rural 722 (21) 1185 (61) 1590 (99) 1027 (85) 1190 (100) 0 (0) 
Urban 2666 (77) 758 (39) 10 (1) 169 (14) 0 (0) 1068 (100) 
Missing 0 (0) 0 (0) 2 (0) 7 (1) 0 (0) 0 (0) 
Bed net ownership       
Yes - 1798 (93) 327 (20) 681 (57) 877 (74) - 
No - 145 (7) 1275 (80) 522 (43) 313 (26) - 
Missing 3388 (100) 0 (0) 0 (0) 0 (0) 0 (0) 1068 (100) 
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Table 6.1 Continued. 
 FSP/ 
MISAME- BF  
(N=1020) 
STOPPAM- 
Benin  
(N=791) 
STOPPAM-
Tanzania 
(N=789) 
ITN- Kenya  
 
(N=711) 
EMEP/IPTp 
MON-Kenya 
(N=471) 
Sek-PNG 
 
(N=293) 
ECHO- DRC 
 
(N=164) 
Study enrollment (years) 2006-2008 2008-2010 2008-2010 1996-1999 2011-2013 2005-2007 2005-2006 
Maternal age 23 (19.5-28) 25 (22-30) 26 (22-31) 24 (20-30) 24 (20-30) 24 (21-28) 27 (23.5-31) 
Gravidity        
1 (Primi-) 205 (20) 147 (19) 162 (21) 127 (18) 94 (20) 115 (39) 43 (26) 
2 (Secundi-) 216 (21) 173 (22) 201 (25) 118 (17) 77 (16) 54 (18) 22 (13) 
3+ (Multi-) 599 (59) 471 (59) 426 (54) 466 (66) 300 (64) 124 (42) 99 (60) 
Trimester*        
1 385 (38) 174 (22) 88 (11) 3 (0) 67 (14) 0 (0) 6 (4) 
2 595 (58) 616 (78) 701 (89) 376 (53) 247 (52) 214 (73) 158 (96) 
3 40 (4) 1 (0) 0 (0) 292 (41) 140 (30) 75 (26) 0 (0) 
Missing GA 0 (0) 0 (0)  0 (0) 40 (6) 17 (4) 4 (1) 0 (0) 
Anemic†        
Yes 372 (36) 354 (45) 289 (37) 416 (59) 169 (36) 272 (93) 43 (26) 
No 630 (62) 433 (55) 497 (63) 293 (41) 297 (63) 21 (7) 107 (65) 
Missing 18 (2) 4 (1) 3 (0) 2 (0) 5 (1) 0 (0) 14 (9) 
HIV        
Yes - 13 (2) 39 (4) 51 (7) 0 (0) - 4 (2) 
No - 699 (88) 693 (88) 234 (33) 468 (99) - 160 (98) 
Missing 1020 (100) 79 (10) 57 (7) 426 (60) 3 (1) 293 (100) 0 (0) 
Area of Residence        
Rural 1020 (100) 791 (100) 430 (55) 711 (100) 471 (100) 282 (96) 0 (0) 
Urban 0 (0) 0 (0) 354 (45) 0 (0) 0 (0) 8 (3) 164 (100) 
Missing 0 (0) 0 (0) 5 (1) 0 (0) 0 (0) 3 (1) 0 (0) 
Bed net ownership        
Yes - 254 (32) 571 (72) 348 (49) - 240 (82) 164 (100) 
No - 537 (68) 52 (7) 363 (51) - 49 (17) 0 (0) 
Missing 1020 (100) 0 (0) 166 (21) 0 (0) 471 (100) 4 (1) 0 (0) 
Categorical variables are expressed as N (%) and continuous variables are expressed as median (IQR). Dash indicates information on particular factor was not 
assessed in parent study. BF=Burkina Faso. DRC=Democratic Republic of the Congo. GA=gestational age. HIV=human immunodeficiency virus. PNG=Papua 
New Guinea. * Based on ultrasound if measured, otherwise based on Ballard’s score or symphysis-pubis fundal height (SFH). When using SFH, to adjust for 
misclassification in the first trimester, a fundal height< 7 cm was defined as first trimester, while SFH<28 cm was defined as second trimester, and SFH≥28cm 
defined as third trimester. † Anemic= hemoglobin <11 g/dL of venous blood, if available, or hematocrit <33%, in the first and third trimesters, and less than 10.5 
and 32, respectively for the second trimester. 
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Figure 6.1. Prevalence of malaria infection at enrollment, malnutrition (MUAC<23cm or BMI < 18.5 kg/m2), and joint malaria infection and malnutrition 
among 14,633 live birth pregnancies from women participating in studies (years 1996-2015) included in the Maternal Malaria and Malnutrition (M3) initiative. 
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Figure 6.2. The independent effects of (a) malaria infection at enrollment and (b) malaria infection at delivery on risk of low birthweight and mean birthweight 
among women enrolled in one of thirteen studies from the Maternal Malaria and Malnutrition (M3) initiative. Inverse probability of treatment weighted (IPTW) 
estimates controlled for confounding between malaria at enrollment and LBW by maternal age, gravidity, area of residence, mid-upper arm circumference at 
enrollment, and HIV infection (where available). IPTW estimates controlled for confounding between malaria at delivery and LBW additionally controlled for 
anemia and number of doses of antimalarial intermittent preventive therapy received during pregnancy. aRR= adjusted risk ratio. BF=Burkina Faso. 
BW=Birthweight. CI= Confidence interval. DRC=Democratic Republic of the Congo. LBW=Low birthweight. N/A=not available. N/C= no model convergence. 
PNG=Papua New Guinea. 
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Figure 6.3. The independent effect of malnutrition at enrollment, (a) MUAC<23cm and (b) BMI*<18.5 kg/m2), on risk of low birthweight and mean birthweight 
among 14,633 women enrolled in one of thirteen studies from the Maternal Malaria and Malnutrition (M3) initiative from 1996 to 2015. BMI adjusted for 
gestational age to reflect estimated first trimester weight. Inverse probability of treatment weighted (IPTW) estimates controlling for confounding between 
malnutrition (MUAC or BMI) at enrollment and LBW by maternal age, gravidity, area of residence, anemia, and HIV infection (where available). BMI=Body 
mass index. BW=Birthweight. CI= Confidence interval. DRC=Democratic Republic of the Congo. MUAC=mid-upper arm circumference. N/A=not available. 
N/C= no model convergence. PNG=Papua New Guinea. 
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Supplemental Figure 6.1. Prevalence of low mid-upper arm circumference (MUAC<23cm) compared to prevalence of low body-mass index (BMI< 18.5 kg/m2) 
among the thirteen studies in the Maternal Malaria and Malnutrition (M3) initiative. 
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Supplemental Figure 6.2. Meta-regression results for the effects of malaria infection at enrollment and delivery on risk of low birthweight (LBW) and mean 
birthweight (BW) by time period, study type, location, and malaria infection prevalence. Median malaria infection prevalence across studies was 17% at 
enrollment and 15% at delivery. RCT=randomized control trial. 
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Supplemental Figure 6.3. Meta-regression results for the effects of malnutrition at enrollment, (a) low mid-upper arm circumference (MUAC<23cm) and (b) 
low BMI (BMI<18.5 kg/m2), on risk of low birthweight (LBW) and mean birthweight (BW) by time period, study type, location, and malaria infection 
prevalence. Median malaria infection prevalence across studies was 17% at enrollment and 15% at delivery. RCT=randomized control trial.
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Supplemental Figure 6.4. Meta-regression results for the multiplicative and additive interaction effects for malaria infection at enrollment or delivery and low 
mid-upper arm circumference (MUAC<23cm) on risk of low birthweight (LBW) and mean birthweight (BW) by time period, study type, location, and malaria 
infection prevalence. Median malaria infection prevalence across studies was 17% at enrollment and 15% at delivery. 
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 Supplemental Figure 6.5. Prevalence malaria infection at delivery among the thirteen studies in the Maternal Malaria and Malnutrition (M3) initiative. 
 
 
 
K
isum
u-K
enya
IP
Tp-P
N
G
IS
Tp-M
alaw
i
S
TO
P
M
IP
-K
enya
LAIS
-M
alaw
i
FS
P
/M
IS
AM
E
-B
F
S
TO
P
P
AM
-B
enin
S
TO
P
P
AM
-Tanzania
ITN
-K
enya
E
M
E
P
 &
 IPTpM
O
N
-K
enya
S
ek-P
N
G
E
C
H
O
-D
R
C
P
r
e
v
a
l
e
n
c
e
  89
Supplemental Table 6.1. Selected sensitivity analyses results for the multiplicative interaction effects for malaria 
and malnutrition on risk of adverse birth outcomes among the thirteen studies in the Maternal Malaria and 
Malnutrition (M3) initiative. Sensitivity analyses varied the definitions of malaria, malnutrition, and the approach 
taken in pooling study results, and are stratified by outcome definition.  
Malaria Definition Malnutrition Definition Method Product term* (95% CI) 
LBW    
Enrollment MUAC<23 cm Two-stage 1.30 (0.62, 2.72) 
Enrollment MUAC<23 cm Two-stage† 1.44 (0.64, 3.25) 
Enrollment BMI<18.5 kg/m2 Two-stage 1.26 (0.77, 2.05) 
Enrollment MUAC<23 cm One-stage 1.12 (0.71, 1.78) 
Delivery MUAC<23 cm Two-stage 0.82 (0.50, 1.33) 
Delivery BMI<18.5 kg/m2 Two-stage 0.90 (0.56, 1.45) 
Enrollment- with PCR MUAC<23 cm Two-stage 1.57 (0.81, 3.05) 
Delivery- with PCR MUAC<23 cm Two-stage 0.80 (0.41, 1.56) 
Any malaria‡ MUAC<23 cm Two-stage 1.29 (0.70, 2.38) 
Any malaria‡ BMI<18.5 kg/m2 Two-stage 0.82 (0.54, 1.24) 
SGA    
Enrollment MUAC<23 cm Two-stage 0.94 (0.47, 1.85) 
Enrollment BMI<18.5 kg/m2 Two-stage 1.01 (0.46, 2.21) 
Delivery MUAC<23 cm Two-stage 1.72 (0.85, 3.48) 
Delivery BMI<18.5 kg/m2 Two-stage 0.82 (0.17, 3.85) 
BMI=body mass index. BW=birth weight. CI= confidence interval LBW=low birthweight. MUAC=mid-upper arm 
circumference. PCR=polymerase-chain reaction. SGA=small-for-gestational age. * Estimate of the departure from 
multiplicative interaction. † Analysis included only birth weights measured within 24 hours of delivery. ‡Any 
malaria infection defined as a positive LM, RDT, or PCR at enrollment, delivery, or during pregnancy (among 
studies that were able to retrospectively share repeat diagnostics during pregnancy). 
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CHAPTER VII: INTERVENTIONS AGAINST MATERNAL MALARIA AND 
MALNUTRITION: POTENTIAL IMPACT ON PREGNANCY OUTCOMES 
 
Introduction 
Low birthweight (LBW) remains a significant global health concern, affecting over 25 
million infants annually (16,17). Defined as birth weight less than 2,500 grams, LBW is 
associated with a marked increase in infant mortality and contributes to long-term morbidity (5). 
In 2012, the WHO endorsed a target to reduce the incidence of LBW by 30% by 2025. As of 
2014, the Global Nutrition Report found that there was little progress globally towards this goal 
(21). Interventions in low- and middle-income countries (LMICs) to improve fetal growth have 
the potential to produce substantial public health effects, improving a wide array of factors 
ranging from cognitive development to enhanced neonatal survival. 
Two important risk factors for LBW in many LMICs are maternal malnutrition and 
malaria infection during pregnancy (1,2,44,51). In malaria-endemic countries, up to one in four 
pregnant women are infected with malaria during pregnancy, and estimates of malnutrition 
prevalence also reach as high as 20% among women of reproductive age in LMICs (1,17,46). 
While these two factors are highly prevalent in many LMICs, they are often studied and 
intervened upon independently. Our group, the Maternal Malaria and Malnutrition (M3) 
Initiative, has endeavored to better understand this co-burden of malaria infection and 
malnutrition during pregnancy. Specifically, in a recent publication using data pooled from 
thirteen studies across sub-Saharan Africa and the Western Pacific, we found that women who 
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were both infected with malaria and malnourished were at greater risk of delivering a LBW 
infant than their uninfected, well-nourished counterparts, and that malnutrition in particular has a 
strong effect on LBW (REF Paper 1 “Malaria, Malnutrition, and Birth Weight: A Pooled 
Analysis of 14,633 Pregnancies”).  
While results from this study were informative for furthering our understanding of the 
biologic mechanisms that affect fetal growth and development, they do not address the public 
health impact of intervening on malaria infection and malnutrition during pregnancy. Policy 
makers may wish to know how many LBW infants could be prevented by intervening to prevent 
malaria infection during pregnancy or maternal malnutrition. The current WHO Policy 
Recommendations for malaria prevention during pregnancy involve three separate evidence-
based strategies: insecticide treated bed nets (ITN), intermittent preventive therapy during 
pregnancy (IPTp), and effective case management (32). The current strategy for IPTp involves 
monthly doses of sulfadoxine/pryimethamine (SP) starting in the second trimester (32). Despite 
an increase in the proportion of women receiving IPTp, the level of coverage remains inadequate 
(39–41). Additionally, interventions to address maternal malnutrition during pregnancy have not 
been programmatically integrated into antenatal care (51,145).  
The objective of this study was two-fold. First, we aimed to estimate the impact of 
implementing hypothetical targeted antimalarial and nutritional interventions on population-level 
estimates of LBW. State-of-the-art epidemiologic methods allow us to use complex, real-world 
data to estimate the effects of plausible public health interventions (13,65,146,147). Second, we 
aimed to see if the introduction of any combination of these hypothetical targeted antimalarial 
and nutritional interventions might meet the WHO goal of a 30% reduction in LBW. These 
results have the potential to improve guidelines for clinical practice among this population and 
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provide motivation for development or improvement of interventions to address the dual burden 
of malaria and malnutrition on pregnancy outcomes. 
Methods 
Study population 
The study population comprised 14,633 live birth pregnancies pooled together in the 
Maternal Malaria and Malnutrition (M3) initiative, although the sample sizes for each specific 
analysis depended on the availability of relevant data. The M3 initiative has been described in 
detail previously (68). Briefly, the study population consisted of pregnant women enrolled in one 
of thirteen studies conducted from 1996 to 2015 in Sub-Saharan Africa (seven countries) and the 
Western Pacific (one country). Parent studies were initially undertaken with a range of objectives 
related to investigating the etiology of malaria during pregnancy, evaluating antimalarial 
interventions during pregnancy, such as IPTp or ITN, or assessing the effectiveness of nutritional 
supplementation during pregnancy.  
Outcome and exposures 
The main outcome of interest for this proposed work was LBW (3). Every study 
measured birth weight (BW) within one week of delivery, and BW measured after 24 hours 
(13% of weights) was adjusted using a regression model to account for subsequent changes in 
weight during the first week of life, and weights measured after 24 hours were excluded in a 
sensitivity analysis (143). Presence of malaria parasitemia in peripheral blood or in the placenta 
at delivery was assessed using light microscopic (LM) examination of a Giemsa-stained 
peripheral or placental smear and/or placental histology (active or past infection) (90). Given the 
variation in availability of polymerase chain reaction (PCR) diagnostics across studies and the 
uncertain impact of sub-microscopic infections on adverse birth outcomes, we excluded PCR 
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results from our definition of malaria infection (92). Most studies had some strategy for malaria 
prevention during pregnancy, either as part of a randomized control trial or as the national policy 
during the study period. Information on how many doses of IPTp women received was available 
for 92% of the study population, and self-reported bed net ownership at study enrollment was 
also ascertained in nine out of the thirteen studies. However, data on bed net ownership did not 
distinguish between untreated and insecticide-treated bed nets (ITN), although most recent 
studies will have been ITN. Currently, the WHO recommends use of SP for IPTp, which is what 
a majority (64%) of the women received, but some women did receive SP with azithromycin 
(16%), SP plus chloroquine (15%), or dihydroartemisinin-piperaquine (5%) (32). We used mid-
upper-arm circumference (MUAC) at study enrollment as our primary measure of maternal 
malnutrition, categorizing women as malnourished if their MUAC was less than 23 cm and as 
well-nourished otherwise (93). MUAC is an indicator of maternal protein reserves, fat stores, and 
malnutrition more broadly (93). We used gestational-age-adjusted body-mass index less than 
18.5 kg/m2 as a secondary anthropometric indicator of malnutrition. 
Population Intervention Effects 
Table 7.1 describes a series of contrasts between observed and counterfactual population 
distributions of malaria infection, IPTp dosage, bed net ownership, and maternal MUAC. First in 
Table 7.1, we show the comparison of the risk of LBW if the population of women had all been 
infected with malaria at delivery (all-shaded circle) versus if none of the population had been 
infected (unshaded circle). While this estimate informs on the etiologic effect of malaria 
infection at delivery, it is a contrast of two counterfactual exposure distributions and tells us little 
about the real-world impacts of reducing malaria infection at delivery. To further understand the 
implications of implementing interventions to reduce malaria infection at delivery, we compared 
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the observed distribution of malaria infection at delivery (the partially-shaded circle) to the 
hypothetical population in which no women were infected with malaria (the unshaded circle; 
Table 7.1, scenario 2). (REF Westreich et al, in press at Epidemiology, “From patients to policy: 
population intervention effects in epidemiology”). Although hypothetical and not based on a 
specific antimalarial intervention, this contrast provides our best estimate about what would 
happen if malaria infection at delivery were completely eliminated. 
To better guide policies for specific evidence-based interventions, we also assessed the 
impact of scaling up existing malaria prevention efforts implemented in the pooled studies, 
specifically (i) bed net ownership at enrollment and (ii) IPTp prophylaxis during pregnancy. 
Unlike the prior etiologic and intervention effects where we were considering complete 
elimination of malaria, now we are specifically estimating the impact of the scale-up of existing 
malaria prevention strategies. For bed net ownership at enrollment, we compared the observed 
distribution of bed net ownership (approximately 62% of participants with available information 
on bed net ownership) to a counterfactual scenario in which everyone owns a bed net (Table 7.1, 
scenario 3). To inform the population-level impact of scaling up IPTp in malaria endemic 
settings, we compared the observed distribution of IPTp doses to the hypothetical population in 
which everyone has i) at least two doses of IPTp or ii) at least three doses of IPTp (similar to the 
monthly schedule recommended by the WHO since 2007) (Table 7.1, scenario 4) (32). Given 
that the national target for many of the malaria-endemic countries represented by our study 
population is 80% coverage, we also assessed increasing the dosage to at least three doses of 
IPTp in 80% of the study population (Table 7.1, scenario 4) (40). 
Table 7.1 also details population-level contrasts between observed or counterfactual 
distributions of maternal malnutrition in early pregnancy, as defined by low MUAC. We took a 
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similar approach to this exposure as we did to malaria, first comparing the risk of LBW if the 
population of women all had MUAC below 23 cm (all-shaded circle) versus if all of the women 
had MUAC at or above 23 cm (unshaded circle), and then comparing the observed distribution of 
MUAC (the partially-shaded circle) to the hypothetical population in which women had MUAC 
at or above 23 cm (unshaded circle) (Table 7.1, scenarios 5-6). Women with MUAC 
counterfactual to these scenarios were set either below or above the cut point of 23 cm depending 
on the contrast. For example, in the scenario where all women were simulated to have normal 
MUAC, a woman with factual MUAC of 20 cm would have their simulated MUAC set to 23 cm, 
improving their nutritional status to a normal measurement of MUAC. Additionally, it is 
unrealistic to expect that an intervention could achieve complete removal of maternal 
malnutrition; therefore we also compared the observed distribution of malnutrition prevalence at 
enrollment to the population in which only 5% of each separate study population is malnourished 
at enrollment (the lowest prevalence of malnutrition from any of our studies).  
Statistical Analysis 
We used the parametric g-formula to estimate the aforementioned population intervention 
effects detailed in Table 7.1. The parametric g-formula has been described in detail previously 
(13,14,148). Briefly: first, we modeled the effect of each exposure (malaria, malnutrition, bed net 
ownership, or IPTp dosage) on LBW. We used logistic regression models, controlling for known 
and measured confounders, and generalized estimating equations to account for within-study 
correlation. Confounders for the relationship between malaria infection at delivery and LBW 
were determined from a causal directed acyclic graph (DAG) (116) based on prior literature on 
the relationship between covariates, and included study site, maternal age, gravidity, rural versus 
urban residence, HIV infection, anemia at enrollment, and the number of IPTp doses. 
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Confounders for the malnutrition-LBW relationship were obtained from a separate DAG and 
included study site, maternal age, gravidity, rural versus urban residence, anemia at enrollment, 
and HIV infection. Study site was the only measured confounder for the bed net coverage-LBW 
relationship and study site and HIV infection were the only measured confounders for the IPTp-
LBW relationship.  
Second, we “set” the exposure (malaria, malnutrition, IPTp use, or bed net coverage) to 
the level specified for the particular hypothesized intervention (see Table 7.1). With this 
exposure “set” (sometimes counter to the fact of the observed exposure), we predicted the 
probability of the outcome (having a LBW infant) for each individual.  
 Third, we averaged the imputed probabilities for having a LBW infant for each individual 
across the population, for each “set” level of exposure. Comparison of the average outcomes for 
the different “set” exposure provides us with population-wide predicted effect of changing 
exposure on the prevalence of LBW in the whole population, a population-standardized risk 
difference for the specified exposure contrast. We also estimated the number needed to treat 
(NNT) for each contrast of “set” exposures (except for the unrealistic contrasts of all exposed 
versus non-exposed), as the reciprocal of the absolute value of the risk difference. NNTs for 
hypothesized interventions that are only targeted towards the exposed were calculated as the 
prevalence of the exposure times the reciprocal of the absolute value of the risk difference. 
Confidence intervals were calculated using a non-parametric bootstrap (200 samples with 
replacement from original dataset) (117).  
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Results 
Study Population 
Characteristics of the 14,633 women participating in the thirteen M3 studies have been 
reported previously, and are included in Supplemental Table 7.1. While a majority of studies 
enrolled between 20% to 30% primigravida women, some studies, such as the Kisumu, Kenya, 
study and the IPTp-PNG study, enrolled roughly 50% primigravida women. The variation in 
prevalence of anemia was also noticeable, with the lowest prevalence of 26% in ECHO-DRC 
and the highest prevalence of 93% in the Sek PNG study.  The observed overall prevalences of 
malaria infection at delivery, IPTp doses, bed net, and distribution of MUAC at study enrollment 
are depicted in Figure 1. Specifically, 2,312 (20%) of the 11,832 women with malaria 
diagnostics were infected with malaria at delivery and 1,224 (14%) of the 8,963 women with 
MUAC measured were malnourished at enrollment (low MUAC) (Figure 1). However, these 
prevalences varied greatly by study site, with the prevalence of malaria at delivery ranging from 
<1% (0.3%) to 57% and the prevalence of malnutrition ranging from 5% to 54% (Supplemental 
Table 7.1). The median number of IPTp doses among the 13,485 women with IPTp dosage 
information was 1 (interquartile range: 0, 3) and 5,260 (62%) of the 8,516 women reported 
owning a bed net (Figure 7.1). The prevalence of LBW was 9% (range 5% to 15%). 
Intervention Estimates 
The population-standardized risk differences relating to malaria infection at delivery or 
antimalarial interventions are displayed in Table 7.2. The risk difference for LBW when 
comparing the population had everyone been infected with malaria at delivery versus if none of 
the population had been infected was 2.6% (confidence interval [CI]: 1.1%, 3.8%). The 
population attributable risk difference was smaller (RD: 0.6% [95% CI: 0.2%, 0.8%]) because it 
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compared the observed prevalence of malaria (where only 20% of women overall were infected) 
to complete elimination of malaria infection. 
We then estimated the effects for scaling up existing interventions of bed net ownership 
and IPTp. The risk difference for the comparison of observed bed net ownership to the 
population had everyone owned a bed net was 0.4% (95 CI: -0.2%, 1.0%). The risk difference 
for at least two doses of IPTp compared to the observed distribution was modest (0.6% [95% CI: 
-0.3%, 1.4%]), but the effect for increasing the dosage to three doses for all women was 
markedly stronger (RD: 2.9% [95% CI: 2.2%, 3.6%]; NNT: 36 [95% CI: 28, 46]). Increasing 
dosage to 3+ for at least 80% of the study population also produced substantial impacts on LBW 
(RD: 2.1% [95% CI: 1.6%, 2.6%]), albeit weaker than complete IPTp 3+ coverage. Results were 
consistent when excluding women with non-SP exclusive regimens (i.e. SP with azithromycin, 
SP plus chloroquine, or dihydroartemisinin-piperaquine) and when excluding infants with birth 
weight measured after 24 hours. 
The population-standardized risk differences relating to maternal malnutrition at 
enrollment are shown in Table 7.3. The risk difference for LBW when comparing the population 
had everyone had low MUAC at study enrollment versus if all of the population had MUAC at 
or above 23 cm was 4.0% (95% CI: 3.0%, 5.1%). The risk differences for LBW were smaller 
when comparing the observed distribution of MUAC to the population had there been no 
malnutrition (RD: 0.3%, 95% CI: [0.2%, 0.4%]) or to the population where only 5% of each 
study was malnourished (RD: 0.2%, 95% CI: [0.2%, 0.3%]). The population-standardized risk 
differences when using BMI as an anthropometric indicator of maternal malnutrition were 
weaker (Supplemental Table 1).  
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Discussion 
In this work we calculated intervention estimates for the potential impact of reductions in 
malaria infection at delivery, scale-up of bed net ownership and intermittent preventive therapy 
(IPTp) during pregnancy, and reductions in maternal malnutrition during early pregnancy on the 
risk of delivering a low birthweight (LBW) infant using data from thirteen studies in malaria-
endemic countries in sub-Saharan Africa and the Western Pacific. Calculation of interventional 
effects is rarely done in epidemiologic studies, despite the utility of such results from a policy 
and public health perspective (13,65,146,147). Most epidemiologic studies estimate the effects of 
specific exposures, contrasting hypotheticals in which everyone is exposed, compared to 
everyone who is unexposed (REF Westreich et al, in press at Epidemiology, “From patients to 
policy: population intervention effects in epidemiology”, (149)). However, these exposure effect 
estimates may be less valuable for policy decision-makers when considering interventions or 
changes in clinical practice, protocols, or guidelines (13,14,65,149,150). Overall, these results 
showed that increasing uptake of IPTp has the potential to have a marked impact on the numbers 
of infants born LBW in malaria endemic countries.  
The absolute difference in the risk of LBW of 2.6% when comparing the extreme contrast 
in which everyone is infected with malaria at delivery, compared to everyone who is uninfected, 
illustrates the harmful impact of maternal parasitemia on the risk of LBW. This etiologic effect is 
consistent with the other etiologic effect measures for malaria infection reported in prior work by 
the M3 initiative and by other observational studies related to malaria infection during pregnancy 
(REF Paper 1 “Malaria, Malnutrition, and Birth Weight: A Pooled Analysis of 14,633 
Pregnancies”, (19)). We previously reported that women infected with malaria at delivery had an 
average risk of LBW that was 1.3 times greater than uninfected women (adjusted risk ratio: 1.32 
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(95% CI: 1.08, 1.62) (REF Paper 1 “Malaria, Malnutrition, and Birth Weight: A Pooled Analysis 
of 14,633 Pregnancies”). Our risk difference reported here is consistent with that relative effect, 
and is perhaps the more relevant measure for assessing public health impact (151). In addition to 
estimating the etiologic effects of malaria infection at delivery on LBW, we also provided 
estimates for the effect of interventions that would hypothetically eliminate existing malaria 
infection at delivery. Complete elimination of malaria infection at delivery in these settings 
seems possible, given that at least one of the studies had a prevalence of malaria infection at 
delivery that was only 0.3%, and given the current global drive to malaria elimination. However, 
our population attributable effect illustrates that even if we were to completely remove malaria 
infection within these settings, there would only be a 0.6% absolute reduction in the prevalence 
of LBW.  
The population attributable effect for bet net ownership was also notably weak: we 
estimated that a complete uptake of bed net ownership would only result in a 0.4% absolute 
reduction in the prevalence of LBW compared to current levels over all studies in this cohort. 
However, in our pooled data set, 62% of women with available information reported owning a 
bed net at enrollment. This is likely an overestimate: as of 2010 ITN coverage in sub-Saharan 
Africa was only 41% (5,40,152). If bed net ownership is overestimated, the actual population 
intervention estimate is likely greater than we estimated. Furthermore, M3 only captured 
information on bed net ownership; actual usage of the bed nets may be even lower. Additionally, 
while we did control for study site in our model, we did not have more detailed information on 
malaria transmission, regional insecticide residence, or most importantly whether or not the bed 
nets were untreated or insecticide-treated, which may influence the validity of our results. A 
2009 Cochrane Review summarizing information from five randomized controlled trials found 
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that insecticide-treated bed nets were effective at reducing the risk of LBW (RR 0.77, 95% CI: 
0.61, 0.98) among women (153). Given the limitations surrounding our measurement of bed net 
usage, we urge caution in the interpretation of the bed net results, emphasizing that bed nets, in 
particular insecticide-treated bed nets, remain a valuable tool for preventing malaria and 
improving fetal development in malaria-endemic countries (152,153). 
Conversely, our results suggest that scaling up existing coverage of IPTp to three or more 
doses could have a marked impact on the absolute number of infants born LBW. We estimated 
that, had all individuals under study had at least three doses of IPTp during pregnancy, the 
incidence of LBW could have been reduced from 8.5% to 5.6%, a 33% (95% CI: 25%, 43%) 
relative reduction. This reduction in LBW exceeds the WHO 2025 Global Nutrition Target of a 
30% reduction in LBW, and corresponds to an NNT of 36. Even 80% coverage of 3+ was 
estimated to reduce LBW by a 24% (95% CI: 19%, 29%) relative reduction. However, the 
effects for IPTp are stronger than the estimated effect of complete elimination of malaria 
infection at delivery . This discrepancy could be related to the fact that increased IPTp coverage 
indicates treatment and prevention of malaria throughout pregnancy and not just at delivery, 
which was not something we captured in our malaria analysis. However, it could also suggests 
that the apparent effect of IPTp may be attributable to other mechanisms than the prevention of 
malaria infection at delivery. In regards to other mechanisms, SP, the primary drug used for IPTp, 
is an effective broad-spectrum antibiotic in addition to an antimalarial and may improve fetal 
growth through clearance of other pathogens, anti-inflammatory action, and/or alteration of gut 
microbiome composition (154,155). However, we also cannot discount potential unmeasured 
confounding and selection bias influencing the validity of these results. First, the intervention 
estimates for IPTp do not account for regional drug resistance. However, a recent multi-country 
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study found that even in areas of high-resistance to SP, IPTp-SP remains associated with 
reductions in the risk of LBW (79). Second, women who receive three or more doses of IPTp are 
likely receiving earlier and more frequent antenatal care. Women who have the resources and 
ability to access frequent antenatal care are potentially healthier due to associated health-
promoting behaviors and related socio-economic status (156,157).  Our inability to control for 
these potential unmeasured confounders and selection biases indicates that our intervention 
effects may be biased and that the impact of IPTp may not be as great as we have estimated. 
Future studies are warranted that attempt to elucidate the various mechanisms of action for SP 
and to untangle to effects of increased dosage with the potential selection bias related to more 
frequent antenatal care. Despite these limitations, these findings are consistent with prior 
evidence on the importance of multiple doses of IPTp during pregnancy (34). Recent 
mathematical modeling conducted by Walker and colleagues also indicated substantial 
reductions in LBW through increasing IPTp coverage (158). While there has been an increase in 
the proportion of women receiving IPTp over the past decade, the level of coverage remains 
inadequate (39–41). In 2013, an estimated 43% of the 35 million eligible pregnant women did 
not receive even a single dose of IPTp (41). Our findings provide further incentive for increasing 
the uptake of IPTp coverage.  
In addition to the intervention effects for malaria and antimalarial exposures, we also 
reported intervention effects for maternal malnutrition. The absolute difference in the risk of 
LBW when comparing the extreme contrast of everyone being malnourished at study enrollment 
(MUAC<23 cm), compared to everyone being well-nourished (RD: 4.0% [95% CI: 3.0%, 5.1%]), 
is consistent with prior publications that highlight significant associations between maternal 
anthropometrics and fetal development (REF Paper 1 “Malaria, Malnutrition, and Birth Weight: 
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A Pooled Analysis of 14,633 Pregnancies”, (48,52)). However, we estimated that even if we 
were to improve the nutritional status of all women to a normal MUAC by a novel, hypothetical 
intervention, there would only be a 0.3% absolute reduction in the incidence of LBW, and that a 
more realistic reduction of low MUAC prevalence to 5% by a novel, hypothetical intervention 
would still only result in a 0.2% absolute reduction in the incidence of LBW. Thus, while low 
MUAC is a strong predictor of LBW, our intervention effects illustrate that complete or partial 
removal of this risk factor from this population would have only faint population-level impacts 
on LBW. However, despite the minimal population-level impact, our ‘number needed to treat 
(NNT)’ results suggest that a hypothetical nutritional intervention targeted towards only 
malnourished women could be an efficient approach to addressing the burden of LBW. 
Specifically, if this hypothetical intervention was provided to only women that were 
malnourished, then the number of women who would need to receive the hypothetical nutrition 
intervention to see one less infant born LBW is 43 (95% CI: 34, 63). Results were similar, 
although weaker, when using body mass index as an anthropometric indicator (Supplemental 
Table 7.2). 
Unlike the malaria interventions, where we were able to assess real interventions (bed 
nets and IPTp), we were not able to assess a real nutrition intervention, but rather had to rely on 
assuming a hypothetical intervention on maternal anthropometrics. We only had malnutrition 
assessments at antenatal enrollment, thus our nutrition models require the assumption that an 
intervention could be implemented that would target malnutrition prior to pregnancy or in early 
pregnancy. For example, an aggressive community-based anti-malnutrition campaign targeted at 
women of reproductive age could potentially produce the changes in maternal malnutrition that 
we model. There has been a push by nutritional researchers to move beyond prenatal nutritional 
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interventions, and to expand the focus to maternal nutrition to the periconceptional period as well 
(44). This is further supported by animal studies showing that protein deficiencies during the 
peri-implantation and rapid placental development stages significantly affect fetal growth (44). 
Alternatively, there are prenatal dietary supplementation interventions that could be given to 
women who present undernourished to antenatal care early in pregnancy, such as lipid-based 
nutrient supplements or balanced protein energy supplementation, but these interventions are 
unlikely to have a marked impact on maternal MUAC in such a short time period. Future studies 
may wish to consider using measurement of gestational weight gain to estimate impacts of 
hypothetical nutritional interventions that would improve gestational weight throughout 
pregnancy.  
In additional to the aforementioned limitations, the extent of unmeasured confounding 
biasing results is unknown. For example, potential unmeasured confounders include helminth 
infection, sexually transmitted infections, environmental pollutants, or micronutrient deficiencies. 
Additionally, all of the intervention effects reported are a function of background prevalences of 
the exposure of interest in each analysis, thus not generalizable to settings with dramatically 
different baseline prevalences. Supplemental Figure 1 illustrates the distribution of risk 
differences for increasing IPTp uptake for each of the studies, with varying levels of exposure 
and covariate prevalences.  
Public Health Implications 
In conclusion, our intervention effects provide valuable information to policy makers 
regarding the scale-up of malaria prevention, specifically IPTp, during pregnancy. Provision of 
interventional effects in addition to exposure effects provides results that are more immediately 
useful to policy-makers. For example, outputs from this work could be directly used in cost-
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effectiveness models created by health policy professionals for understanding the impact of 
scaling up IPTp. Additionally, while the IPTp estimates were notably strong, hypothetical 
interventions to partially or even completely reduce malaria or improve MUAC do not appear to 
have a strong impact on population-level incidence of LBW.  Although we cannot discount 
potential unmeasured confounding and selection bias of the IPTp estimates, if we assume that 
they are valid then this suggests that IPTp-SP improves fetal growth through mechanisms 
independent of both malaria and malnutrition. 
Overall, our findings highlight the impact that scaling up of this existing antenatal 
intervention could have on the absolute numbers of infants born LBW. Of interventions 
evaluated in this work, early antenatal initiation and frequent antenatal follow-up to ensure 
adequate dosage of IPTp throughout pregnancy appears to be a key tool for achieving the 
WHO’s Global Nutrition Target of a 30% reduction in LBW by 2025.  
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Table 7.1. Population average causal effects, population attributable effects, and generalized intervention effects for 
the risk of low birthweight (LBW) associated with malaria infection and malnutrition during pregnancy. For 
example, the second scenario depicts the population attributable effect for malaria infection at delivery, comparing 
the risk of LBW under the observed distribution of malaria infection at delivery in the study population to the risk 
under a counterfactual setting in which there is hypothetical complete and instant eradication of malaria.  
 Exposure (s) Contrasts Intervention 
 Malaria interventions 
1 Malaria 
infection at 
delivery 
Population average causal effect: The population with everyone 
exposed to malaria infection at delivery compared to the population of 
women with no infection. 
 
N/A 
2 Malaria 
infection at 
delivery  
Population attributable effect: 
The observed distribution of malaria infection at delivery compared to 
the population of women with no infection. 
 
Hypothetical complete and 
instant eradication of 
malaria infection at 
delivery. 
3 Bed net 
ownership at 
enrollment 
Population attributable effect:  The observed distribution of bed net 
ownership compared to the population of women where everyone owns 
a bed net. 
 
Scaling up of existing bed 
net intervention. 
4 Number of 
IPTp doses 
Generalized intervention effect:  The observed distribution of 
intermittent preventive therapy during pregnancy (IPTp) doses compared 
to the population where (i) everyone has at least two doses of IPTp, (ii) 
everyone has at least three doses of IPTp, or (iii) at least 80% of the 
study population has at least three doses of IPTp. 
 
 
 
Scaling up of existing 
IPTp interventions. 
 Malnutrition interventions 
5 Malnutrition 
at enrollment 
Population average causal effect: The population with everyone 
malnourished at enrollment compared to the population of women with 
no malnutrition. 
 
N/A 
6 Malnutrition 
at enrollment 
Population attributable effect:  The observed distribution of 
malnutrition (MUAC<23 cm) compared to the population of women 
with no malnutrition. 
 
Hypothetical complete and 
instant eradication of 
malnutrition prior to 
pregnancy or in early 
pregnancy. 
7 Malnutrition 
at enrollment 
Generalized intervention effect:  The observed distribution of 
malnutrition (MUAC<23 cm) compared to the population where only 
5% of each separate study population is malnourished. 
 
Hypothetical intervention 
with a non-specific 
mechanism that would 
reduce malnutrition 
prevalence in each study 
in M3 to 5%  
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Figure 7.1. Distribution of malaria infection at delivery, number of doses of intermittent preventive therapy during 
pregnancy (IPTp), bed net ownership at study enrollment, and maternal mid-upper arm circumference of women 
enrolled in studies participating in Maternal Malaria and Malnutrition (M3) cohort initiative from 1996 to 2015. 
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Table 7.2. Estimated population-level impact of malaria infection during pregnancy and potential interventions to 
reduce malaria infection on low birthweight among women enrolled in studies participating in Maternal Malaria and 
Malnutrition (M3) cohort initiative from 1996 to 2015. 
 Contrasts 
Risk of 
LBW 
Risk difference  
(95% CI) NNT 
Malaria infection at delivery     
N=11,826 (2,312 infected)     
Population average causal effect     
All exposed 
 
10.5% 2.6% (1.1%, 3.8%)  
None exposed 7.9% 0.  
Population attributable effect     
Observed 
 
8.5% 0.6% (0.2%, 0.8%) 181 (120, 405)  
None exposed 7.9% 0.  
Bed net ownership      
N=8,516 (5,260 owned bed net)     
Population attributable effect     
Observed 
 
9.7% 0.4% (-0.2%, 1.0%) 253 (-620, 101) 
All exposed   9.3%   
IPTp dosage     
N=13,483 (Avg 1.5 doses)     
Population attributable effect     
Observed (3623 [27%] with 3+)  8.5%   
All at least 2 doses  7.9% 0.6% (-0.3%, 1.4%) 423 (-320 73) 
All 3+ doses  5.6% 2.9% (2.2%, 3.6%) 36 (28, 46) 
80% of each study 3+ doses  6.4% 2.1% (1.6%, 2.6%) 51 (39, 64) 
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Table 7.3. Estimated population-level impact of maternal malnutrition (low mid-upper arm circumference [MUAC]), 
and potential interventions to reduce malnutrition on low birthweight among women enrolled in studies participating 
in Maternal Malaria and Malnutrition (M3) cohort initiative from 1996 to 2015. 
  
Risk of 
LBW 
Risk difference 
(95% CI) 
NNT 
Maternal Malnutrition      
N=8,963 (1,224 with low MUAC)     
Population average causal effect     
All exposed 
 
13.6% 4.0% (3.0%, 5.1%)  
None exposed 9.6% 0. 
 
Population attributable effect     
Observed 
 
9.9% 0.3% (0.2%, 0.4%) 312 (243, 424) † 
None exposed 9.6% 0. 43 (34, 63) ‡ 
Generalized intervention effect     
Observed 
 
9.9% 0.2% (0.2%, 0.3%) 439 (336, 579) † 
Exposure reduced to realistic 
lower bound (5%)* 9.7%  61 (47, 90) ‡ 
* The lowest prevalence of malnutrition (MUAC<23cm) within the pooled M3 dataset was observed in the 
STOPMIP-Kenya cohort (5%). 
† Number needed to treat, assuming an intervention that is administered to all women to improve their nutrition, 
regardless of their baseline nutrition level. 
‡ Number needed to treat, assuming an intervention that is only administered to women that were malnourished at 
baseline.  
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Supplemental Table 7.1. Characteristics of women participating in thirteen studies included in the Maternal Malaria and Malnutrition (M3) initiative. 
 Kisumu- 
Kenya 
(N=3388) 
IPTp-PNG 
(N=1943) 
ISTp-
Malawi 
(N=1602) 
STOPMIP-
Kenya  
(N=1203) 
LAIS-Malawi 
 
(N=1190) 
iLiNS-Ghana 
 
(N=1068) 
Study enrollment (years) 1996-2001 2009-2013 2011-2013 2012-2015 2003-2006 2009-2012 
Maternal age 20 (18-24) 24 (20-28) 21 (18-26) 22 (19-27) 24 (20-29) 26 (22-30) 
Gravidity       
1 (Primi-) 1656 (49) 966 (50) 542 (34) 403 (34) 267 (22) 349 (33) 
2 (Secundi-) 748 (22) 494 (21) 448 (28) 237 (20) 213 (18) 351 (33) 
3+ (Multi-) 984 (29) 573 (29) 612 (38) 563 (47) 710 (60) 368 (34) 
Anemic†       
Yes 2548 (75) 1348 (69) 533 (33) 591 (49) 459 (39) 305 (29) 
No 808 (24) 512 (26) 1069 (67) 612 (51) 731 (61) 763 (71) 
Missing 32 (1) 83 (4) 0 (0) 0 (0) 0 (0) 0 (0) 
HIV       
Yes 810 (24) - 0 (0) 0 (0) 144 (12) 0 (0) 
No 2560 (76) - 1602 (100) 1203 (100) 931 (78) 1059 (99) 
Missing 18 (1) 1943 (100) 0 (0) 0 (0) 115 (10) 9 (1) 
Malaria (LM or histology) 624 (19) 288 (15) 470 (30) 436 (37) 14 (3) NA 
IPTp doses 0 (0-0) 1 (1-3) 0.5 (0-4) 1 (0-2) 4 (2-4) - 
Bed net ownership       
Yes - 1798 (93) 327 (20) 681 (57) 877 (74) - 
No - 145 (7) 1275 (80) 522 (43) 313 (26) - 
Missing 3388 (100) 0 (0) 0 (0) 0 (0) 0 (0) 1068 (100) 
Low MUAC (<23 cm) NA 541 (28) NA 65 (5) NA 82 (8) 
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Supplemental Table 7.1 Continued. 
 FSP/ 
MISAME- BF  
(N=1020) 
STOPPAM
- Benin  
(N=791) 
STOPPAM
-Tanzania 
(N=789) 
ITN- 
Kenya  
(N=711) 
EMEP/IPTp 
MON-Kenya 
(N=471) 
EMEP/IPTp 
MON-Kenya 
(N=473) 
Sek-PNG 
(N=293) 
ECHO- 
DRC 
(N=164) 
Study enrollment (years) 2006-2008 2008-2010 2008-2010 1996-1999 2011-2013 2011-2013 2005-2007 2005-2006 
Maternal age 23 (19.5-28) 25 (22-30) 26 (22-31) 24 (20-30) 24 (20-30) 24 (20-30) 24 (21-28) 27 (23.5-
31) 
Gravidity         
1 (Primi-) 205 (20) 147 (19) 162 (21) 127 (18) 94 (20) 94 (20) 115 (39) 43 (26) 
2 (Secundi-) 216 (21) 173 (22) 201 (25) 118 (17) 77 (16) 77 (16) 54 (18) 22 (13) 
3+ (Multi-) 599 (59) 471 (59) 426 (54) 466 (66) 300 (64) 302 (64) 124 (42) 99 (60) 
Anemic†         
Yes 372 (36) 354 (45) 289 (37) 416 (59) 169 (36) 170 (35) 272 (93) 43 (26) 
No 630 (62) 433 (55) 497 (63) 293 (41) 297 (63) 298 (63) 21 (7) 107 (65) 
Missing 18 (2) 4 (1) 3 (0) 2 (0) 5 (1) 5 (1) 0 (0) 14 (9) 
HIV         
Yes - 13 (2) 39 (4) 51 (7) 0 (0) 0 (0) - 4 (2) 
No - 699 (88) 693 (88) 234 (33) 468 (99) 486 (99) - 160 (98) 
Missing 1020 (100) 79 (10) 57 (7) 426 (60) 3 (1) 3 (1) 293 (100) 0 (0) 
Malaria (LM or histology) 46 (6) 83 (13) 2 (0.3) 147 (22) 10 (9) 10 (9) 168 (57) 24 (15) 
IPTp dosage 2 (1-2) 2 (2-2) 3 (3-3) 0 (0-0) 3 (2-3) 3 (2-3) - 2 (2-2) 
Bed net ownership         
Yes - 254 (32) 571 (72) 348 (49) - - 240 (82) 164 (100) 
No - 537 (68) 52 (7) 363 (51) - - 49 (17) 0 (0) 
Missing 1020 (100) 0 (0) 166 (21) 0 (0) 471 (100) 473 (100) 4 (1) 0 (0) 
Low MUAC (<23 cm) 53 (5) 40 (6) 73 (9) 66 (11) NA NA 157 (54) 19 (12) 
Categorical variables are expressed as N (%) and continuous variables are expressed as median (IQR). Dash indicates information on particular factor was not assessed in parent 
study. BF=Burkina Faso. DRC=Democratic Republic of the Congo. GA=gestational age. HIV=human immunodeficiency virus. IPTp=intermittent preventive treatment in 
pregnancy. LM=light microscopy. MUAC=mid-upper arm circumference. PNG=Papua New Guinea. * Based on ultrasound if measured, otherwise based on Ballard’s score or 
symphysis-pubis fundal height (SFH). When using SFH, to adjust for misclassification in the first trimester, a fundal height< 7 cm was defined as first trimester, while SFH<28 
cm was defined as second trimester, and SFH≥28cm defined as third trimester. † Anemic= hemoglobin <11 g/dL of venous blood, if available, or hematocrit <33%, in the first 
and third trimesters, and less than 10.5 and 32, respectively for the second trimester. 
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Supplemental Table 7.2. Estimated population-level impact of maternal low BMI, and potential interventions to 
reduce malnutrition on low birthweight among 14,633 women enrolled in Maternal Malaria and Malnutrition (M3) 
cohort initiative from 1996 to 2015. 
  
Risk of 
LBW 
Risk difference 
(95% CI) 
NNT 
Maternal Malnutrition     
 
Low BMI    
 
N=14,322 (1,287 with low BMI)     
Population average causal risk 
difference     
All exposed  11.1% 2.5%   
None exposed  8.5% 
(1.9%, 3.3%) 
 
Population attributable contrast     
Observed  8.6% 0.08%  1217 (907, 1805) 
† 
None exposed  8.5% 
(0.06%, 0.11%) 
109 (82, 162) ‡ 
Generalized intervention contrast     
Observed  8.6% 0.06%  1837(1342, 2692)
 † 
Exposure reduced to realistic lower 
bound (3%)*  8.6% 
(0.04%, 0.08%) 
165 (121, 242) ‡ 
* The lowest prevalence of low BMI within the pooled M3 dataset was observed in the ISTp-Malawi dataset (3%). 
† Number needed to treat, assuming an intervention that is administered to all women to improve their nutrition, 
regardless of their baseline nutrition level. 
‡ Number needed to treat, assuming an intervention that is only administered to women that were malnourished at 
baseline.  
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Supplemental Figure 7.1. The population attributable effect of increases IPTp dosage to at least three doses for all 
pregnancies, stratified by the parent studies. This figure does not incorporate the variance of each estimate. The 
overall prevalence of 3 or more doses of IPTp=27%, corresponding to an overall population attributable risk 
difference of 2.9% (2.2%, 3.6%). 
 
  
R
is
k
 D
if
fe
re
n
c
e
 (
%
)
  114
 
CHAPTER VIII: DISCUSSION 
Overview 
Despite widespread, well-supported public health campaigns over the past two decades to 
scale up malaria prevention programs for pregnant women, the prevalence of malaria infection 
during pregnancy remains around 25% in highly-endemic countries, a considerable public health 
burden. Malaria infection during pregnancy can have detrimental effects on the newborn, 
including low birthweight (LBW, <2,500g), which itself is associated with increased infant 
morbidity and mortality and adulthood health problems.  
Evidence from four prior studies indicated that the relationship between malaria infection 
and LBW may be influenced by the mother’s nutritional status. Two studies found a significant 
association between malaria infection and measures of fetal growth among malnourished 
pregnant women (defined using low mid-upper arm circumference [MUAC] or low body mass 
index [ BMI]), but little or no association among well-nourished women. Two additional studies 
had inconsistent results. The first aim of this dissertation was to investigate the potential 
interaction between malaria infection and maternal undernutrition (low MUAC or low BMI) with 
regard to LBW, by pooling data from 14,633 pregnancies from malaria-endemic countries. We 
hypothesized that there would be a synergistic interaction between malaria infection and 
malnutrition in causing LBW, such that the observed joint effect of being both infected with 
malaria and malnourished would be greater than expected if considering each exposure 
independently. Our second aim was to translate our etiologic estimates related to the effects of 
malaria and malnutrition during pregnancy on LBW into intervention estimates that would 
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inform on the absolute reduction in LBW that could be seen in malaria-endemic countries with 
hypothetical antimalarial and nutritional interventions.  
Summary of findings 
 The M3 dataset comprised eleven studies from across sub-Saharan Africa and two studies 
from Papua New Guinea, representing a diverse study population of 14,633 pregnant women 
from multiple settings. While the prevalence of malaria infection at enrolment and delivery was 
overall fairly common (16% of women were infected at study enrolment and 20% of women 
were infected at delivery), the prevalence varied across studies. Similarly, while the prevalence 
of low MUAC and low BMI was 14% and 9%, respectively, these prevalences also varied across 
studies. When considering the dual burden of malaria infection and malnutrition at the 
population level, among 8,152 women with both measurements, only 2% had both low MUAC 
and malaria infection at enrollment; proportions were similar when low BMI instead of MUAC.  
Aim 1 
 The results of Aim 1 contribute to the sparse body of literature that had previously 
addressed the interaction between malaria infection and malnutrition with regard to LBW. We 
found that women who were both infected with malaria and malnourished during pregnancy had 
a greater risk of delivering a baby with LBW and reduced mean birthweight compared to their 
uninfected, well-nourished counterparts. While these risks were greater than the individual risks 
of malaria infection and malnutrition separately, there was no evidence of excess risk due to 
interaction on either the multiplicative or additive scale. There was apparent multiplicative 
interaction between malaria infection at enrollment and low MUAC with regards to LBW among 
an a priori analysis restricted to African studies, but this was not statistically significant when 
properly accounting for multiple comparisons, and was absent when using other definitions of 
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malaria (i.e. at delivery) or malnutrition (i.e. BMI). And notably, the additive interaction, which 
has been argued at the more relevant measure for public health impact (114), was only slightly 
elevated among the African studies only and was not strong or precise enough to warrant public 
health action. Also of public health relevance, only 183 women (2%) were jointly infected and 
malnourished (low MUAC). Thus, even if there were a multiplicative interaction between 
malaria infection and MUAC among African women, the proportion of women implicated is 
small, and does not indicate a large public health burden. Overall, while not all analyses are 
consistent with a completely null finding, there was overall no convincing evidence of synergism, 
i.e. excess risk due to interaction, that would warrant public health significance.  
We also provided updated evidence on the independent consequences of maternal malaria 
infection and malnutrition in a large and diverse population. Even in the absence of strong 
interaction between malaria infection and malnutrition on LBW, our findings emphasize that 
malaria infection and malnutrition represent two established and modifiable causes of LBW that 
should be considered as targets of combined interventions to optimize pregnancy outcomes in 
low- and middle-income countries. 
Aim 2 
The findings of Aim 2 further elucidate the implications of targeted interventions related 
to malaria and malnutrition on the population-level burden of low birthweight.  Of the 
hypothetical antimalarial and nutritional interventions evaluated in this work, the most notable 
interventional estimate was associated with scaling up IPTp dosage to three or more doses during 
pregnancy. This is aligned with the 2007 WHO recommendations for monthly IPTp-SP during 
pregnancy starting in the second trimester. While the IPTp estimates were notably strong, 
hypothetical interventions to partially or even completely reduce malaria or improve MUAC do 
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not appear to have much impact on population-level incidence of LBW.  Although we cannot 
discount potential unmeasured confounding and selection bias of the IPTp estimates, if we 
assume they are valid then this suggests that IPTp-SP improves fetal growth through 
mechanisms independent of both malaria and malnutrition.  
Strengths 
 This work rigorously addressed the previously unclear relationship between malaria 
during pregnancy, maternal malnutrition, and LBW. Prior pregnancy studies that assessed 
malaria infection-undernutrition interactions have had small sample sizes, and more subjects 
from more study sites were needed to determine the magnitude and generalizability of the 
combined effect, particularly within Africa. Prior work also exclusively focused on how 
malnutrition did or did not modify the relationship between malaria and LBW, rather than the 
interaction between the two risk factors. Our work expanded upon this framework by evaluating 
maternal malaria infection and malnutrition as co-primary exposures with putative synergistic 
pathways of interaction. Interaction is preferable to EMM because interventions for both malaria 
infection and malnutrition might prevent LBW.  
 Our work harmonized data from thirteen different parent studies into a large, robust 
dataset, coined the Maternal Malaria and Malnutrition (M3) Initiative dataset, providing malaria 
epidemiologists with an unprecedented and highly valuable data resource for other potentially 
high impact research questions. The M3 dataset includes combined data from 12,395 pregnancies 
from eight African countries and 2,236 pregnancies from Papua New Guinea, for a total of 
14,633 pregnancies in malaria-endemic areas. To our knowledge, this is the largest study to date 
to assess interactions between malaria infection, malnutrition, and LBW, enlarging the study 
population within Africa by almost ten-fold compared to prior research. Compilation of these 
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studies also provided us with a large, diverse study population with increased generalizability. 
The study population draws from a diverse setting of rural and urban areas, representing a wide 
range of malaria transmission and malnutrition prevalences, as well as diversity in modifying 
factors, such as gravidity, HIV infection, and maternal anemia.  
 Availability of individual data, rather than just aggregate data from each study, further 
enabled us to synchronize our definitions of exposures and outcomes where possible and 
minimize measurement heterogeneity. We used modern and appropriate statistical analyses to 
account for between-study variation, confounding, and missing data. Data pooled from different 
patient populations is sometimes incorrectly analyzed as one large dataset, however this ignores 
variation in the effect estimates across studies due to differences in patient populations, study 
procedures, study location, and calendar time. We strengthened our analysis by conducting a 
two-step approach to analyzing our pooled data, as well as confirming our findings using a one-
stage generalized mixed model with random effects. Furthermore, in our two-stage analysis, we 
also calculated 95% population effects intervals (PEI). PEI are rarely reported in meta-analyses, 
despite their importance in incorporating the estimated variance between studies (111). To 
handle confounding, we appropriately used inverse probability of treatment weights to separately 
adjust for exposure-specific confounders. This was necessary since anemia at enrollment was a 
mediator of the malaria infection at enrollment-LBW relationship and a confounder of the 
malnutrition-LBW relationship. 
 Our work is further strengthened by the emphasize on providing results that are more 
readily translatable to policy decisions in Aim 2. To our knowledge, no one has calculated and 
reported interventional effect estimates for the impact of hypothetical targeted antimalarial and 
malnutrition interventions on pregnancy outcomes, specifically LBW. Provision of interventional 
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effects in addition to exposure effects provides results directly useful to policy-makers. For 
example, output from this work could be directly applied to cost-effectiveness models used by 
health policy professionals for understanding the impact of implementing and/or scaling up 
interventions on malaria and malnutrition. 
Limitations 
 The main limitations of the pooled M3 dataset are related to missing data and 
heterogeneity of collected data. Information that was collected by all studies varied, leading to 
systematically missing data on a number of important variables. Notably, not all studies collected 
data on maternal mid-upper arm circumference, the preferred anthropometric for defining 
maternal macronutrient malnutrition. While we did have BMI measurements on a majority of 
women, BMI changes throughout pregnancy due to maternal and fetal weight gain, thus we were 
limited to extrapolating a pre-pregnancy BMI using gestational age and BMI at enrollment. The 
availability of consistent and frequent malaria diagnostics was also a limiting factor. We were 
obliged to pool malaria diagnostics of varying sensitivity and specificity, and we were limited to 
two cross-sectional assessments of malaria infection. Nevertheless, sensitivity analyses that 
evaluated alternative definitions of malaria, or incorporated repeat diagnostics during pregnancy, 
were consistent with the main results. 
 Additionally, there may be selection bias in both aims due to conditioning on fetal 
survival, also called left truncation or competing risk bias. Left truncation occurs when a study 
includes participants who enter the study after they have already been at risk for the outcome of 
research interest. This occurs in pregnancy studies where women are often not enrolled until 
their first antenatal care visit or later, due to the difficulty of following women from conception, 
especially in resource poor settings. Typically, this left truncation is assumed to be non-
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informative, and analyses are restricted to live singleton pregnancies as a result. Thus, 
pregnancies that ended in miscarriage or stillbirth may be missing from the study due to 
enrollment restrictions or missing from the analysis due to exclusion criteria. However, when 
there are differential rates of early pregnancy losses among those who are exposed and 
unexposed (singly or jointly exposed), this could cause a selection bias potentially distorting the 
true causal associations (139). This has also been described as bias resulting from survival 
selection by conditioning on a competing risk (159).  
 As illustrated in Figure 8.1, restricting analyses to only live births could potentially be 
restricting on a collider if there is an unmeasured factor that influences both pregnancy loss and 
fetal growth and if both malaria and malnutrition affect pregnancy loss. This unmeasured factor 
(U) is a realistic problem, given that there are likely genetic or environmental factors that affect 
both successful live birth and appropriate fetal growth. Additionally, studies of malaria infection 
during pregnancy suggest an increased risk of miscarriage and stillbirth due to malaria infection 
(28,160). To address this potential bias, four of the individual studies, the STOPMIP-Kenya, 
EMEP-Kenya, FSP/MISAME-Burkina Faso, and ISTp-Malawi, agreed to share all pregnancy 
outcomes, including miscarriages and stillbirths, which was not part of the original data request 
for the M3 cohort initiative. However, there were only 116 (3%) pregnancy losses in four studies 
(N=4,571) in M3 that collected these data, limiting our ability to further address this selection 
bias issue.  However this is almost certainly an underestimate, since many studies enrolled 
women after the first trimester. Additional instances of selection bias might also have resulted 
from the sample of studies available and the selection of women into these studies. The M3 was 
a convenience sample of studies with available malaria and nutrition measurements, rather than a 
random sample of extant data, and thus may not be fully representative. Furthermore, women 
  121
enrolled in studies were likely healthier and received better antenatal care than the general 
population; the effects of malaria and malnutrition in reality might well be greater than observed 
within these research settings.  
 As mentioned previously, LBW is limited as an outcome because it is a result of 
intrauterine growth restriction, preterm birth, or both. Additionally, LBW does not distinguish 
between infants who were constitutionally small versus those that truly experienced pathological 
intrauterine growth restriction. The distribution of constitutionally small babies may differ across 
different ethnicities, and we did not account for this difference across the various studies 
included in our analysis.  
 Finally, inherent in most observational data is the extent of unmeasured confounding 
biasing results. As identified through our posited DAG in Figure 4.1, potential unmeasured 
confounders include helminth infections, sexually transmitted infections, environmental 
pollutants, or micronutrient deficiencies; however, it is important to note that because neither 
malnutrition nor malaria could be randomized, large-scale, multi-site cohort analyses such as this 
one are necessarily the gold standard for addressing these scientific questions. Additional 
limitations specific to the second aim included selection bias for the IPTp analysis, 
mismeasurement of bed net usage, and limited availability of more appropriate measures of 
maternal nutrition during pregnancy (such as gestational weight gain) or real nutritional 
interventions (e.g. supplementation).  
Most of the aforementioned limitations are related to the causality assumptions required to 
identify and consistently estimate effect estimates. Specifically, these assumptions are 
conditional exchangeability, treatment-version irrelevance, positivity, no measurement bias, no 
interference, and no model misspecification. Most of these assumptions are still likely required 
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for estimating intervention effects. For example, positivity, no interference, no measurement bias, 
and no model misspecification all still need to be assumed for g-formula estimation of 
intervention effects. As for conditional exchangeability, the assumption is slightly less restrictive. 
In the population average causal effect, where you are coming the study population if everyone 
was exposed versus if no one was exposed, your are assuming that those who are unexposed can 
‘stand in’ (i.e. are exchangeable) for those who are exposed, if they have been exposed, and vice 
versa. However, intervention effects, where one contrast is the observed exposure, you only have 
one-sided conditional exchangeability, such that the exposed need to be exchangeable with the 
unexposed, but you do not need the unexposed to be exchangeable with the exposed. For 
treatment-version irrelevance, you likely are less restrictive again because you are forced to be 
more specific when specifying the intervention that is being simulated in the intervention 
contrast.  
Future directions 
 As previously discussed, our work was limited to primarily analyzing LBW and mean 
BW. In sensitivity analyses conducted in aim 1, we did evaluate SGA as a secondary outcome, 
but future work may seek to repeat the analyses of aim 2 using SGA as an additional outcome. 
Further, while we did attempt to asses SGA, we didn’t assess preterm birth. Preterm birth could 
be assessed using this data among a sub-group of the study population with reliable gestational 
age (ultrasound measurements). Although SGA and preterm birth share common risk factors, 
they are two distinct phenomena with differing etiology, and LBW does not differentiate 
between the two (3). One recent study estimated that approximately half of LBW babies in low- 
to middle-income countries are preterm (23), higher than previously assumed (24).  
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 Future studies may also wish to explore joint effects of malaria with other nutritional 
indicators, such as height, obesity, and anemia. Maternal height is typically interpreted as a 
measure of stunting, chronic/childhood nutritional status and a proxy for low SES, whereas BMI 
and MUAC are more reflective of current nutritional status and represent the reserves available 
to nourish the developing fetus. Mechanisms of putative interaction between height and malaria 
infection could be due to chronic undernutrition affecting endocrinological and immune function 
responses to malaria infection. The potential interaction between anemia and malaria would be 
harder to disentangle, given the cyclical relationship between the two. The second aim of our 
work was focused on hypothetical antimalarial and nutrition interventions during pregnancy. 
Future work would ideally expand upon this work, to evaluate interventional effects for other 
risk factors for impaired fetal growth, such as sexually transmitted infections.  
 One area for future exploration is the complex relationship between malaria, malnutrition, 
and iron deficiency. Studies to date focusing on macronutrient malnutrition, malaria, and LBW, 
including this one, are potentially biased by inadequate control for confounding by maternal iron 
deficiency. Iron deficiency and macronutrient health are highly correlated, since both factors are 
influenced by a common cause, insufficient dietary consumption. Iron deficiency is associated 
with low birthweight (161), but unlike macronutrient health, has a very intricate relationship with 
malaria risk (162,163). There is evidence showing that iron deficiency is protective against 
malaria (162), and that iron supplementation could possibly increase the risk of malaria infection 
and severity (161,163). Undoubtedly, iron deficiency is tightly interconnected with the 
relationship between malaria, macronutrient malnutrition, and LBW. Confounding by iron 
deficiency potentially masks the interaction between malaria and macronutrient malnutrition in 
causing LBW. To adequately control for confounding by iron deficiency in the assessment of 
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interaction between malaria, macronutrient malnutrition, and LBW, one would need to conduct a 
longitudinal study where blood samples are collected and test not just for malaria but for ferritin 
and transferrin co-receptors as biomarker measurements of maternal iron status. The study would 
need to be longitudinal in nature to capture the temporality of malaria infection and iron 
deficiency, due to the cyclical nature of these two factors (Figure 8.2).  
Conclusions 
In conclusion, our work contributes to the body of evidence supporting a harmful impact 
of malaria infection during pregnancy and maternal malnutrition on low birthweight of the baby, 
and the potential impact that scaling up IPTp could have on the absolute numbers of infants born 
LBW. In the largest study to do so, we assessed potential interactions between malaria infection 
and malnutrition with regards to LBW, and overall found no convincing evidence of synergistic 
interaction that would warrant public health action. However, one public health action that is 
strongly supported by our work is the use of multiple doses of IPTp during pregnancy in malaria-
endemic countries, given the impact this intervention can have on the overall burden of LBW.  
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Figure 8.1. Simplified directed acyclic graph (DAG) illustrating potential selection bias due to restriction to live 
births. 
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Figure 8.2. Simplified directed acyclic graph (DAG) illustrating the temporality between mid-upper arm 
circumference (MUAC), iron deficiency (ID), malaria (mala), and low birthweight (LBW).    
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